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A B S T R A C T
Background
Crohn’s disease (CD) is a chronic relapsing inflammatory condition and maintenance of remission is a major issue as many patients
fail to achieve remission with medical management and require surgical interventions. Purine analogues such as azathioprine (AZA)
and 6-mercaptopurine (6-MP) have been used to maintain surgically-induced remission in CD, but the effectiveness, tolerability and
safety of these agents remains controversial.
Objectives
To assess the efficacy and safety of purine analogues (AZA and 6-MP) for maintenance of surgically-induced remission in CD.
Search methods
We searched PubMed, MEDLINE, Embase, CENTRAL, and the Cochrane IBD Group Specialized Register from inception to 26
July 2018 (and from inception to 31 July 2019). In addition, we searched reference lists of all included studies and relevant reviews,
conference proceedings and trials registers.
Selection criteria
Randomised controlled trials (RCTs) with a duration of at least three months that enrolled adults and children with surgically-induced
remission of CD and compared AZA or 6-MP to no treatment, placebo or any other active intervention were considered for inclusion.
Data collection and analysis
Two authors independently assessed trial eligibility, extracted data, assessed the risk of bias and assessed the certainty of the evidence
using GRADE. The primary outcome was clinical relapse. Secondary outcomes included endoscopic relapse, radiologic and surgical
relapse, adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs and health-related quality of life.
Main results
Ten RCTs with a total of 928 participants were included. Study participants were adults recruited from university clinics and gas-
troenterology hospitals who received interventions post-surgery for a duration between 12 to 36 months. Most study participants were
recruited less than three months after surgery in all except one study where participants were recruited between 6 to 24 months post-
surgery. One study was rated as low risk of bias, six studies were rated high risk of bias and three were rated unclear risk of bias.
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There was moderate certainty evidence that purine analogues are more efficient for preventing clinical relapse than placebo. At 12 to
36 months, 51% (109/215) of AZA/6-MP participants relapsed compared to 64% (124/193) of placebo participants (RR 0.79; 95%
CI 0.67 to 0.92; 408 participants; 3 studies; I² = 0%; moderate certainty evidence). The certainty of the evidence regarding the efficacy
of AZA or 6-MP for maintaining postoperative clinical remission compared to 5-ASA compounds was low. At 12 to 24 months , 64%
(113/177) of purine analogue participants relapsed compared to 59% (101/170) of 5-ASA participants (RR 1.05; 95% CI 0.89 to 1.24;
347 participants; 4 studies; I² = 8%; low certainty evidence). The certainty of evidence that purine analogues are inferior for preventing
postsurgical clinical relapse compared to tumour necrosis factor alpha agents (anti-TNF-α) was very low. At 12 to 24 months, 43%
(29/67) of AZA participants relapsed compared to 14% (10/72) of anti-TNF-α participants (RR 2.89; 95% CI 1.50 to 5.57; 139
participants; 3 studies; I² = 0%; very low certainty evidence).
The effect of purine analogues compounds on AEs compared to placebo or any active treatment was uncertain, as the quality of evidence
ranged from very low to low. After 12 to 24 months, 14% (12/87) of purine analogue participants experienced an AE compared to
10% (8/81) of placebo participants (RR 1.36; 95% CI 0.57 to 3.27; 168 participants; 2 studies; I² = 0%; low certainty evidence). The
effect of purine analogues on AEs compared to 5-ASA agents was uncertain. After 12 to 24 months, 41% (73/176) of purine analogue
participants had an AE compared to 47% (81/171) of 5-ASA participants (RR 0.89; 95% CI 0.74 to 1.07; 346 participants; 4 studies;
I² = 15%; low certainty evidence). The effect of purine analogues on AEs in comparison to anti TNF-α agents was uncertain. At 12
to 24 months, 57% (32/56) of AZA participants had an AE compared to 51% (31/61) of anti-TNF-α participants (RR 1.13; 95%
CI 0.83 to 1.53; 117 participants; 2 studies; I² = 0%; low certainty evidence). Purine analogue participants were more like than 5-
ASA participants to have a SAE (RR 3.39, 95% CI 1.26 to 9.13, 311 participants; 3 studies; I² = 9%; very low certainty evidence), or
to withdraw due to an AE (RR 2.21, 95% CI 1.28 to 3.81; 425 participants; 5 studies; I² = 0%; low certainty evidence). Commonly
reported AEs across all studies included leucopenia, arthralgia, abdominal pain or severe epigastric intolerance, elevated liver enzymes,
nausea and vomiting, pancreatitis, anaemia, nasopharyngitis and flatulence.
Authors’ conclusions
Moderate certainty evidence suggests that AZA and 6-MP may be superior to placebo for maintenance of surgically-induced remission
in participants with CD. There was no clear difference in the number of clinical relapses when purine analogues were compared with
5-ASA agents, however this is based on low certainty evidence. There was very low certainty evidence that AZA and 6-MP are more
likely to result in more serious adverse events (SAEs) and withdrawals due to an AE (low certainty) when compared to 5-ASA agents.
Very low certainty evidence suggests that purine analogues may be inferior to anti-TNF-α agents, however, no firm conclusions can be
drawn. Further research investigating the efficacy and safety of AZA and 6-MP in comparison to other active medications in surgically-
induced remission of CD is warranted.
P L A I N L A N G U A G E S U M M A R Y
Azathioprine and 6-mercaptopurine for the maintenance of surgically-induced remission in Crohn’s disease
What was the aim of this review?
The aim of this review was to understand the benefits and harms of purine analogues (azathioprine (AZA) and 6-mercaptopurine (6-
MP)) used for maintaining remission following surgery in people with Crohn’s disease (CD).
What is Crohn’s disease?
Crohn’s disease is a chronic disease of the gut. The disease is known to constantly change from periods when sufferers have symptoms
(relapse) to periods when the symptoms disappear (remission) for a short time. Symptoms include abdominal pain, diarrhoea and
weight loss. People with Crohn’s disease may undergo surgery to remove diseased parts of their gut. However, their symptoms can
return after a short time. Different drugs can be given to ensure that people with Crohn’s disease are free from symptoms for as long
as possible. However, there are concerns about possible side effects that may arise. Purine analogues (AZA and 6-MP) are a group
of immunosuppressive drugs which have been used for over five decades to manage Crohn’s disease. We researched whether purine
antimetabolites can maintain remission in people with Crohn’s disease after the diseased portion of their gut has been removed.
What are the main results of the review?
The review authors found 10 relevant studies with a total of 928 participants, conducted across several European countries, Israel
and the US. The studies included people with Crohn’s disease over 16 years of age who had undergone surgery and were free from
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symptoms. These studies compared purine analogues with placebo (e.g. a sugar pill), or oral 5-aminosalicylic acid (5-ASA) formulations
or with anti-tumour necrosis factor-alpha (anti-TNF-α) drugs. 5-ASA and anti-TNF- drugs are used reduce inflammation (pain and
swelling) in the gut.
One study was high quality, while six studies were of lower quality and three studies did not report enough information to make
a judgement on quality. Purine analogues are probably better than placebo for maintaining surgically-induced remission of Crohn’s
disease (moderate certainty evidence). The analysis of studies that compared purine antimetabolites to 5-ASA medications found no
difference in the number of people who remained in remission. However, more people who received purine analogues experienced
serious side effects or discontinued treatment due to side effects than those who received 5-ASA (very low and low certainty evidence).
The analysis of studies that compared purine analogues to anti-TNF-α drugs showed that purine analogues were less effective for
maintaining remission of Crohn’s disease after surgery. However, the overall certainty of evidence was very low. Well designed studies
are needed to better understand the benefits and harms of purine analogues compared with anti-TNF- agents and other active drugs
used for Crohn’s disease. Due to sparse data and inconsistent reporting across all studies, the effect of purine analogues on side effects
compared with placebo, 5-ASA or biologics was uncertain. Commonly reported side effects across the studies included leucopenia
(a reduction in the number of white cells in the blood), pancreatitis (inflamed pancreas), arthralgia (joint pain), abdominal pain or
severe epigastric intolerance, elevated liver enzymes, nausea and vomiting, anaemia (low number of red blood cells), nasopharyngitis
(common cold) and flatulence (intestinal gas).
How up-to-date is this review?
The review authors searched for studies that had been published up to 31 July 2019.
Conclusions
There is moderate certainty evidence that AZA and 6-MP may be superior to placebo for maintenance of surgically-induced remission
in participants with Crohn’s disease. There was no clear difference in the number of clinical relapses when purine analogues were
compared with 5-ASA agents, however this was based on low certainty evidence. There was very low certainty evidence that AZA
and 6-MP are more likely to result in more serious side effects and withdrawals due to side effects when compared to 5-ASA agents.
Very low certainty evidence suggests that purine analogues may be inferior to anti-TNF-α agents for preventing relapse, however, no
firm conclusions can be drawn. Further research investigating the benefits and harms of AZA and 6-MP in comparison to other active
medications in surgically-induced remission of CD is warranted.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Azathioprine or 6-mercaptopurine compared to placebo for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: People with surgically-induced remission in Crohn’s disease
Setting: Outpat ient
Intervention: Azathioprine (100-150 mg/ day) or 6-mercaptopurine (1 mg/ kg/ day - 50 mg/ day)
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Azathioprine
or 6-mercaptopurine
Clinical relapse
Follow-up: 12 to 36
months
Study populat ion RR 0.79
(0.67 to 0.92)
408
(3 RCTs)
⊕⊕⊕©
MODERATE1
Clinical relapse de-
f ined as: a CDAI>250
(D’Haens 2008); a
CDAI>150 and 100
point increase f rom
baseline (Mowat 2016)
or a grading score > 2
(Hanauer 2004).
642 per 1,000 508 per 1,000
(430 to 591)
Endoscopic relapse
Follow-up:12 to 36
months
Study populat ion RR 0.85
(0.64 to 1.13)
321
(2 RCTs)
⊕⊕©©
LOW 23
Endoscopic relapse de-
f ined as an endoscopic
score i ≥2 (D’Haens
2008; Mowat 2016)
752 per 1,000 639 per 1,000
(481 to 849)
Radiologic relapse Outcome not reported Not reported
Surgical relapse Outcome not reported Not reported
Adverse events
Follow-up: 12 to 24
months
Study populat ion RR 1.36
(0.57 to 3.27)
168
(2 RCTs)
⊕⊕©©
LOW 4
Reported adverse
events include hair loss,
leukopenia, diarrhoea,
abdominal pain, hepa-
totoxicity and arthralgia4
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99 per 1,000 134 per 1,000
(56 to 323)
Serious adverse events
Follow-up:12 to 36
months
Study populat ion RR 1.78
(0.39 to 8.18)
327
(2 RCTs)
⊕⊕©©
LOW 5
Reported serious ad-
verse events include
arthralgia, pancreat it is,
leucopenia and bowel
obstruct ion
13 per 1,000 23 per 1,000
(5 to 108)
Withdrawal due to ad-
verse events
Follow-up:12 to 36
months
Study populat ion RR 0.90
(0.63 to 1.29)
408
(3 RCTs)
⊕⊕⊕©
MODERATE6
Adverse events lead-
ing to withdrawal in-
cluded abnormal blood
results leading to tem-
porary discont inuat ion
of treatment in 28% of
the part icipants. How-
ever, specif ic details on
reasons for discont inu-
at ion were not clearly
stated
254 per 1,000 228 per 1,000
(160 to 328)
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due serious imprecision (233 events).
2 Downgraded one level due to serious inconsistency ( I² = 64%).
3 Downgraded one level due to serious imprecision (227 events).
4 Downgraded two levels due to very serious imprecision (20 events) and 95%CI which includes appreciable benef it and harm
5 Downgraded two levels due to very serious imprecision (7 events) and 95%CI which includes appreciable benef it and harm5
A
z
a
th
io
p
rin
e
a
n
d
6
-m
e
rc
a
p
to
p
u
rin
e
fo
r
m
a
in
te
n
a
n
c
e
o
f
su
rg
ic
a
lly
-in
d
u
c
e
d
re
m
issio
n
in
C
ro
h
n
’s
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
6 Downgraded one level due to serious imprecision (100 events) and 95% CI which includes appreciable benef it and harm
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B A C K G R O U N D
Description of the condition
Crohn’s disease is a chronic idiopathic inflammatory disorder of
the gastrointestinal tract with an etiology that combines genetic
predisposition, environmental factors and an inappropriate im-
mune response to the gut microbiota which may involve the whole
gastrointestinal tract (Abraham 2009). There is no cure for the
disease, and management strategies are mainly focused on induc-
tion and maintenance of remission. Approximately 75% of pa-
tients with Crohn’s disease will eventually undergo surgical resec-
tion (Bernell 2000), and this can induce remission. However, en-
doscopic recurrence of disease has been reported to be as high as
73% at one year post surgery (Rutgeerts 1990), and clinical relapse
rates have been reported to range from 22 to 55% at five years post
surgery (Williams 1990). There is no standard therapy for the pre-
vention of postoperative recurrence in Crohn’s disease (Hanauer
2001). A number of agents have been studied, but considerable
uncertainty remains as to the efficacy of such treatments.
Description of the intervention
Corticosteroids, the mainstay of treatment of acute exacerbations,
have been used extensively as Crohn’s disease therapy. However,
the chronic use of glucocorticosteroids is limited due to the mul-
tiple adverse reactions and the lack of effectiveness for maintain-
ing remission in Crohn’s disease (Steinhart 2003). 5-aminosali-
cylic acid (5-ASA) agents have been shown to be safe and may be
effective for maintenance of post-surgical remission, although the
existing data suggests that the efficacy of these agents depends on
the ability of these drugs to reach the terminal ileum and colon in
therapeutic concentrations and may have limited clinical efficacy
(Gordon 2011). Probiotics and budesonide do not appear to pro-
vide any benefit for maintenance of surgically-induced remission
in Crohn’s disease (Benchimol 2009; Doherty 2009; Rolfe 2006).
Nitroimidazole antibiotics may reduce the risk of relapse in surgi-
cally-induced remission, however, these agents are not well toler-
ated and are associated with a higher risk of serious adverse events
(Doherty 2009). Studies have demonstrated that tumour necro-
sis factor-alpha (TNF-α) antagonists such as infliximab (Regueiro
2009), or adalimumab (Savarino 2013) may provide a benefit for
reducing the risk of relapse in surgically-induced remission, but
these agents are expensive. Purine analogues such as azathioprine
(AZA) and 6-mercaptopurine (6-MP) have been used in clini-
cal practice for over five decades with a demonstrated efficacy for
the long-term maintenance of remission in both Crohn’s disease
(Chande 2015), and ulcerative colitis (Timmer 2016), and are rel-
atively inexpensive. Evidence suggests that the effect of thiopurine
formulations seem to last for up to five years (Fraser 2002), signif-
icantly reducing the risk of perianal and intestinal surgery (Camus
2013).
How the intervention might work
6-MP and its prodrug AZA which is non-enzymatically degraded
to 6-MP are purine antimetabolites that reduce cell proliferation
and have immune modulating properties. 6-MP is metabolised
to its active component 6-thioguanine nucleotide which compet-
itively interferes with nucleic acid metabolism by inhibiting the
proliferation of T and B lymphocytes and reducing the numbers of
cytotoxic T cells and plasma cells (Lennard 1992; Sahasranaman
2008). There are some trial data which suggest that neutrophil
count is a predictor of induction and maintenance of remission
(Colonna 1994), which may suggest the mechanism of action, al-
though this is not well understood. The major limiting factor for
long term use of AZA and 6-MP agents has been the occurrence
of adverse events in approximately 10% of patients leading to
withdrawal of therapy (Hafraoui 2002), with dose-dependent and
idiosyncratic adverse events occurring. There is evidence which
suggests that thiopurine methyltransferase deficiency accounts
for some of the dose and metabolism-related toxicity to purine
analogues including leucopenia, thrombocytopenia and in the
long-term potentially lymphoma and non-melanoma skin cancer
(Axelrad 2016; Gomollon 2017; Lennard 1989; Weinshilboum
1980), while adverse reactions such as arthralgias, pancreatitis,
hepatitis, nausea, non-pancreatic abdominal pain, rush, fever and
diarrhoea are attributed to hypersensitivity reactions (Sandborn
1996).
Why it is important to do this review
Maintenance of remission in Crohn’s disease is a major issue as
many patients fail to achieve remission with medical manage-
ment and require surgical interventions. Purine analogues have
been used to maintain surgically-induced remission in Crohn’s dis-
ease, but the effectiveness, tolerability and safety of these drugs
remains controversial. Relatively few studies have been published
that investigate the role of AZA or 6-MP for maintenance of re-
mission following surgery in patients with Crohn’s disease. One
multicentre randomised placebo controlled trial involving 81 pa-
tients found a significant reduction in endoscopic recurrence when
AZA was used in conjunction with metronidazole in comparison
to metronidazole alone (D’Haens 2008). In another multicentre
randomised controlled trial, it was concluded that 6-mercaptop-
urine was more effective than either mesalamine or placebo at pre-
venting postoperative recurrence at 24 months following surgery
(Hanauer 2001). However, a single-centre randomised open-la-
bel trial found no significant difference in clinical relapse rates be-
tween AZA and mesalamine (Ardizzone 2004). A previous review
by this team in 2014 found evidence that purine analogues may
be superior to placebo for maintenance of surgically-induced re-
mission in patients with Crohn’s disease, although this was based
on two small studies (Gordon 2014). The results for efficacy out-
comes between purine analogues and 5-ASA agents were uncer-
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tain. However, patients taking purine analogues were more likely
than 5-ASA patients to discontinue therapy due to adverse events.
No firm conclusions could be drawn from the two small studies
that compared AZA to infliximab or adalimumab. Adalimumab
seemed superior to AZA but further research was needed to con-
firm these results. Hence, an up-to-date systematic review using
the Cochrane Collaboration format was indicated to summarise
the current evidence on the use of purine analogues for the main-
tenance of surgically-induced remission in Crohn’s disease.
O B J E C T I V E S
The primary objective was to evaluate the efficacy and safety of
AZA and 6-MP for maintenance of surgically-induced remission
in Crohn’s disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials which compared AZA or 6-MP
agents to either a no treatment control, placebo or any other active
intervention, with treatment durations of at least three months
were considered for inclusion.
Types of participants
Participants of any age and sex with a diagnosis of Crohn’s disease
confirmed by any established method who were in remission fol-
lowing surgery were considered for inclusion. Remission could be
defined by a recognized Crohn’s disease activity index such as the
Crohn’s disease activity index (CDAI) or endoscopy, or by par-
ticipants who have undergone a curative surgical resection, or as
defined by the authors of the primary studies. were considered for
inclusion. Eligible trials could be conducted in any setting (e.g.
single centre or multi-centre).
Types of interventions
The controlled interventions of interest included any randomised
controlled trial that compares oral AZA or 6-MP agents to an no
treatment, placebo or another active intervention for maintenance
of surgically-induced remission. Studies that compare AZA or 6-
MP agents to an intervention that focuses on enteral nutrition,
oral nutrient supplementation, medical foods, probiotics, parental
nutrition or herbal medicines were excluded. We also excluded
dose optimisation studies.
Types of outcome measures
Primary outcomes
The primary outcome measure was clinical relapse as defined by
the primary studies.
Secondary outcomes
The secondary outcome measures included the proportion of par-
ticipants who experienced:
• Endoscopic relapse;
• Radiologic relapse;
• Surgical relapse;
• Histologic relapse;
• Adverse event (as defined by FDA 2018. We also noted
where studies failed to provide sufficient information and simply
report outcome as ‘adverse event’);
• Serious adverse events (as defined by FDA 2018. We also
noted where studies failed to provide sufficient information and
simply report outcome as ‘serious adverse event’);
• Withdrawal due to adverse events; and
• Health-related quality of life (HRQoL).
Adverse events and serious adverse events that are known to be
associated with AZA or 6-MP include:
• Bone marrow suppression: pancytopenia, leucopenia,
neutropenia, thrombocytopenia;
• Hypersensitive reactions: malaise, vomiting, diarrhoea,
rash, hypotension;
• Malignancy;
• Liver function impairment, jaundice;
• Pancreatitis;
• Pulmonary: pneumonitis; and
• Renal: interstitial nephritis.
The outcome measures were reported at the last time point avail-
able (assumed to be at the end of follow-up if not specified) and
the time point specified in the methods as being of primary in-
terest (if this was different from the latest time point available).
However, it was also indicated when studies reported outcomes at
other time points.
Search methods for identification of studies
Electronic searches
For the review update, we searched the following electronic
databases from inception to 26 July 2018:
• MEDLINE;
• Embase;
• PubMed;
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• CENTRAL; and
• Cochrane IBD Group Specialized Register.
No restrictions were placed on language. Note that the searches
were designed to include RCTs conducted on adults and children
participants, but to exclude dose optimisation studies and trials
that compare AZA or 6-MP agents to oral nutrition supplements
(enteral nutrition drinks, tube feeds), medical foods, probiotics,
parenteral nutrition, herbal medicines or a combination of these
modalities. The search strategy was more than one year old prior
to publication of the updated review. Thus, we ran another search
from inception to 31 July 2019 prior to publication. The search
strategies are reported in Appendix 1.
Searching other resources
Reference searching
We searched reference lists from included articles and any exist-
ing relevant reviews. We also searched ongoing trials registered
on ClinicalTrials.gov and the WHO International Clinical Trials
Registry Platform portal.
Abstracts of major gastroenterology meetings
A manual search of abstracts and proceedings submitted to recent
major gastroenterology meetings was performed for the following
journals to identify more trials:
• Gastroenterology (American Gastroenterological
Association);
• Gut (British Society of Gastroenterology);
• American Journal of Gastroenterology (American College
of Gastroenterology); and
• Journal of Pediatric Gastroenterology and Nutrition
(European / North American Society of Paediatric
Gastroenterology, Hepatology and Nutrition).
If a relevant abstract was identified, details of the full study
methodology and results were requested from the authors in order
to allow a thorough assessment of the quality of identified studies.
Data collection and analysis
This updated review was based upon the methods described in
the published protocol (Gordon 2014), and in accordance with
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Selection of studies
The selection of studies included the following steps: title screen-
ing, abstract screening and full-text review. Two authors (MG and
TGH) independently reviewed each article at each stage of selec-
tion. Included and excluded studies were recorded. The two au-
thors (MG and TGH) independently screened the titles using the
titles of the papers that appeared to have even a minor possibil-
ity of inclusion. Adjudication did not occur at the title screening
stage and studies that were ambiguous were included by default.
The two authors (MG and TGH) then independently screened
the abstracts of the articles that report studies with a reasonable
possibility of inclusion. Differences in assessment for inclusion
were resolved by discussion between the two independent inves-
tigators (MG and TGH). Adjudication did not occur at the ab-
stract screening state. Lastly, the two authors (MG and TGH) in-
dependently screened the full text which involved selection of ar-
ticles based on careful examination of the full report. Differences
in assessment for inclusion were resolved by discussion between
the two independent investigators. Adjudication was performed
as needed by a third author (ZIE).
Data extraction and management
A data extraction form was developed to extract information on
relevant features and results of included studies. Two authors (ZIE
and TGH) independently extracted and recorded data on the pre-
defined checklist. Extracted data included the following items:
• Study design: type of RCT, setting, number of
interventions, year, author’s contact;
• Population characteristics: age, sex, disease distribution,
disease duration, site of disease, medication, type and time since
operation, total number of participants originally assigned to
each treatment group;
• Intervention: type and dose of agent;
• Control: no active treatment, placebo, other drugs;
• Concurrent medications; and
• Outcomes: time of assessment, length of follow up, type of
Crohn’s disease activity index used, definitions of remission and
relapse, site of surgery, relapse rates, adverse events.
Assessment of risk of bias in included studies
Two authors (ZEI and TGH) independently assessed bias using
the Cochrane risk of bias tool (Higgins 2011). Adjudication was
performed as needed by a third author (MG). Each domain was
assessed as having a low, high, or unclear risk of bias. Domains
assessed included:
• Sequence generation (i.e. was the allocation sequence
adequately generated?);
• Allocation sequence concealment (i.e. was allocation
adequately concealed?);
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• Blinding (i.e. was knowledge of the allocated intervention
adequately prevented during the study?);
• Incomplete outcome data (i.e. were incomplete outcome
data adequately addressed?);
• Selective outcome reporting (i.e. are reports of the study
free of suggestion of selective outcome reporting?); and
• Other potential sources of bias (i.e. was the study apparently
free of other problems that could put it at a high risk of bias?).
Each domain followed standard definitions used for Cochrane sys-
tematic reviews (Higgins 2011). Study authors were contacted for
further information when insufficient information was provided
to determine the risk of bias.
The overall certainty of the evidence was assessed using the
GRADE approach (Guyatt 2008; Schünemann 2011). The
GRADE approach appraises the quality of a body of evidence based
on the extent to which one can be confident that an estimate of
effect or association reflects the item being assessed. Randomised
trials start as high quality evidence, but may be downgraded due
to: risk of bias (methodological quality), indirectness of evidence,
unexplained heterogeneity, imprecision (sparse data) and publica-
tion bias. The overall quality of the evidence for each outcome was
determined after considering each of these factors and graded as:
• High - we are very confident that the true effect lies close to
that of the estimate of the effect;
• Moderate - we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different;
• Low - our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect; or
• Very low. We have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
Measures of treatment effect
For binary outcomes, risk ratio (RR) estimates and associated two-
sided 95% confidence intervals (CI) were calculated. For nominal
or ordinal outcomes, we calculated the RR with corresponding
95% for each category relative to a reference category. For con-
tinuous outcomes, we calculated the mean difference (MD) and
corresponding 95% CI. If studies in future updates report con-
tinuous outcomes that have been measured using different scales
(e.g. IBDQ and SF-36), we will calculate the standardised mean
difference (SMD) and 95% CI.
Unit of analysis issues
The unit of analysis was the individual participant. We planned to
include cross-over trials if data were available from the first phase
of the study (i.e. before cross-over occurred). For outcomes where
events recur (e.g. clinical relapses, adverse events), we calculated
the proportion of participants who experienced at least one event,
individual events were not counted separately. The studies were
otherwise not anticipated to have repeated observations of out-
comes or multiple treatment events. If studies had randomised
subjects to more than one AZA or 6-MP treatment arm, these
groups would have been combined for the primary analysis.
Dealing with missing data
We collected information on how each trial handled missing data.
When a study appeared to collect and not report all primary out-
comes of interest, the original investigators were contacted to re-
quest missing data. If the original investigators did not provide
the data, this would be noted in the systematic review. For studies
with missing dichotomous data, an intention-to-treat analysis was
performed where participants with missing data were assumed to
have been treatment failures.
Assessment of heterogeneity
We assessed heterogeneity through visual inspection of the for-
est plots and by calculating the Chi² and I² statistics (Boreinstein
2009). For studies that had qualitative homogeneity, statistical
heterogeneity was assessed using the Chi² test (a P value < 0.10
was considered statistically significant heterogeneity). The degree
of heterogeneity across studies was estimated using the I² statis-
tic. An I² of 25% or less was considered low heterogeneity, 26%
to 50% was considered moderate heterogeneity, and 50% and
greater was considered substantial heterogeneity. Where sufficient
data are available, we planned to explore possible explanations for
heterogeneity including factors such as participant characteristics
(e.g. age, sex), condition severity, treatment type and dose, and
healthcare system/country. Where appropriate, these factors were
to be investigated further through sub-group analyses and meta-
regression (Boreinstein 2009). Where sufficient data are available,
we planned to use sensitivity analyses to explore possible causes of
methodological heterogeneity (Sutton 2000).
Assessment of reporting biases
If there were an appropriate number of studies in a pooled analysis
(i.e. > 10 studies), we planed to investigate potential publication
bias using funnel plots (trial effects versus trial size) (Egger 2001).
However, the number of studies in each comparison group was
smaller than 10.
Data synthesis
Data from individual trials were combined for meta-analysis if
the interventions, patient groups and outcomes were sufficiently
similar (determined by consensus). We calculated the pooled RR
and corresponding 95% CI for dichotomous outcomes. Analyses
were grouped by type of intervention treatment (e.g. AZA or 6-MP
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versus placebo, AZA or 6-MP versus 5-ASA). Where there were
multiple studies in an analysis we used a random-effects model
to obtain a more conservative interpretation otherwise, we used a
fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We planned to assess the impact of potential effect modifiers such
as age of participants (paediatric versus adult studies), drug type
(azathioprine versus 6-mercaptopurine) and length of follow-up
(12 months or less versus greater than 12 months). There were no
studies on children.
Sensitivity analysis
Sensitivity analyses based on random-effects versus fixed-effect
models were planned where appropriate data or numbers of stud-
ies were available. Sensitivity analysis was also planned to explore
possible explanations for significant heterogeneity.
R E S U L T S
Description of studies
Results of the search
The original search for this update was conducted on 26 July
2018. The search expired before the update could be published,
so we ran another search on 31 July 2019. The electronic database
search conducted on 31 July 2019 identified 1201 records, while
37 records were found through other sources (See Figure 1). Of
the 52 full-text records assessed for eligibility, 35 reports of 10
studies (928 participants) were included in this systematic review
update. Two studies (NCT03185611; NL1344), were classified
as ongoing Characteristics of ongoing studies. Eleven studies (15
reports) were excluded for different reasons as presented in the
Characteristics of excluded studies table.
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Figure 1. Study flow diagram.
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Detailed information about all included studies are presented in
the Characteristics of included studies table.
Included studies
Study design and setting
This systematic review includes reports of single centre and mul-
ticentre randomised controlled trials with a parallel design with
a duration of 52 weeks (Lopez-Sanroman 2017; Reinisch 2010),
to 36 months (Mowat 2016). These studies were all published
between 2004 and 2017. There were four single-centre stud-
ies conducted in two different countries: Italy (Ardizzone 2004;
Armuzzi 2013; Savarino 2013), and Israel (Scapa 2015). The mul-
ticentre studies were conducted across Belqium (D’Haens 2008),
Spain (Lopez-Sanroman 2017, the UK (Mowat 2016), or as a
multinational collaboration of several countries across Europe
and Israel (Reinisch 2010), and Europe and the USA (Hanauer
2004). Regarding the care setting, three studies were conducted
either in gastroenterology hospitals and medical clinics/centres
(Lopez-Sanroman 2017; Reinisch 2010), and secondary and ter-
tiary hospitals (Mowat 2016), or as a collaboration between uni-
versity clinics and hospitals and medical centres in four studies
(Ardizzone 2004; D’Haens 2008; Hanauer 2004; Savarino 2013).
The country and care setting were not reported in Herfarth 2006.
Participants
The total number of participants included in nine studies was
928 and ranged from 22 participants (Armuzzi 2013), to 240
(Mowat 2016). Scapa 2015 did not clearly report the number of
participants randomised. All participants were adults with Crohn’s
disease who had undergone a resective surgical procedure to re-
move macroscopic disease. The majority of these participants were
recruited within three months of surgery or before hospital dis-
charge, except the 78 participants in Reinisch 2010 who were en-
rolled between 6 and 24 months postoperatively. Interventions
were conducted on participants with quiescent Crohn’s disease
and the disease activity prior to enrolment was established by gen-
erally accepted endoscopic, histological and radiological criteria.
However, it is important to note that Reinisch 2010 included par-
ticipants in subsequent postoperative clinical remission (CDAI <
200), but with signs of moderate to severe endoscopic recurrence.
For this reason we only collected data on adverse events from
Reinisch 2010.
The age of participants was reported nine studies and ranged be-
tween an average of 32.7 years (Scapa 2015), to 40 years (D’Haens
2008) in seven trials. Two trials reported age as median (Armuzzi
2013; Lopez-Sanroman 2017). All studies appear to have been
conducted on a male and female adult population. None of the
studies included paediatric participants. Herfarth 2006 did not
report any information about the age of participants.
Interventions
All included studies were parallel two arm trials except for two
studies that had three intervention arms (Hanauer 2004; Savarino
2013). The duration of the intervention ranged from 52 weeks
(Armuzzi 2013; Herfarth 2006; Lopez-Sanroman 2017; Reinisch
2010; Scapa 2015), to 24 months (Ardizzone 2004; D’Haens
2008; Hanauer 2004; Mowat 2016; Savarino 2013).
The studies compared the efficacy of AZA or 6-MP agents with
placebo or another active treatment. Table 1 reports a summary
of all interventions which are also summarized below:
AZA or 6-MP versus placebo
• AZA versus placebo (D’Haens 2008).
Both intervention arms also received concomitant metronidazole
(750 mg/day) therapy for the first three months of the study (
D’Haens 2008).
• 6-Mercaptopurine versus placebo (Hanauer 2004; Mowat
2016).
AZA or 6-MP versus oral 5-ASA agents
• AZA versus mesalamine (Ardizzone 2004; Herfarth 2006;
Reinisch 2010; Savarino 2013).
• 6-MP versus mesalamine (Hanauer 2004).
AZA or 6-MP versus anti-TNF-α
• AZA versus infliximab (Armuzzi 2013).
• AZA versus adalimumab (Lopez-Sanroman 2017; Savarino
2013).
In Lopez-Sanroman 2017 both intervention arms also received
concomitant metronidazole (750 mg/day) therapy for the first
three months of the study.
• 6-Mercaptopurine versus adalimumab (Scapa 2015).
No studies that compared AZA or 6-MP agents to a no treatment
control group were identified.
The use of concurrent treatment was discussed in all but two stud-
ies (Savarino 2013; Scapa 2015). In one study all participants
were receiving oral metronidazole (500 mg/day) for two weeks
after surgery (Armuzzi 2013), while in two studies both interven-
tion arms were administered metronidazole (ornidazole) for the
first three months after surgery (D’Haens 2008; Lopez-Sanroman
2017). In Mowat 2016 any concomitant therapy had to be well
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documented and there was no reported use of active concomi-
tant treatments. Corticosteroids were allowed to be tapered by
standardized stepwise dose reductions in three studies (Ardizzone
2004; D’Haens 2008; Hanauer 2004). Symptomatic treatment
with antacids, antidiarrhoeal or spasmolytic medication on de-
mand was permitted in three studies but had to be scrupu-
lously recorded (Ardizzone 2004; D’Haens 2008; Hanauer 2004).
D’Haens 2008 permitted topical therapy for perianal disease and
cholestyramine for the treatment of bile-acid diarrhoea. Conti-
nous use of nonsteroidal anti-inflammatory drugs was prohibited
and only occasional use of paracetamol and tramadol was allowed
in Savarino 2013.
Outcomes
Outcomes were reported at multiple time points in two stud-
ies (D’Haens 2008; Mowat 2016), and at a single time point
in eight studies (Ardizzone 2004; Armuzzi 2013; Hanauer 2004;
Herfarth 2006; Lopez-Sanroman 2017; Reinisch 2010; Savarino
2013; Scapa 2015). Some studies had followed participants be-
yond the intervention period, however, outcome data from those
time points were not reported in this review.
Outcomes of interest reported across studies included:
Primary outcomes
• Clinical relapse (Ardizzone 2004; Armuzzi 2013; D’Haens
2008; Hanauer 2004; Herfarth 2006; Lopez-Sanroman 2017;
Mowat 2016; Reinisch 2010; Savarino 2013).
Secondary outcome
• Endoscopic relapse (Armuzzi 2013; D’Haens 2008;
Hanauer 2004; Mowat 2016; Reinisch 2010; Savarino 2013;
Scapa 2015).
• Radiological relapse (Hanauer 2004; Savarino 2013).
• Histologic relapse (Armuzzi 2013).
• Surgical relapse (Ardizzone 2004).
• Adverse events (Ardizzone 2004; D’Haens 2008; Hanauer
2004; Lopez-Sanroman 2017; Reinisch 2010; Savarino 2013).
• Serious adverse events (Ardizzone 2004; Hanauer 2004;
Lopez-Sanroman 2017; Mowat 2016; Reinisch 2010).
• Withrawal due to adverse events (Ardizzone 2004; Armuzzi
2013; D’Haens 2008; Hanauer 2004; Herfarth 2006;
Lopez-Sanroman 2017; Mowat 2016; Reinisch 2010; Savarino
2013).
A summary of interventions and outcomes is presented in addi-
tional Table 2.
Funding and conflict of interest
Four studies were reportedly supported by pharmaceutical com-
panies (Hanauer 2004; Herfarth 2006; Lopez-Sanroman 2017;
Reinisch 2010), but only two declared conflict of interest (Lopez-
Sanroman 2017; Reinisch 2010). The author of one study was
contacted to clarify the role of the pharmaceutical company and he
confirmed that the company had no role in the study design, data
analysis or writing of the paper (Hanauer 2004), whereas the re-
maining authors did not respond. Two studies were not supported
by any grant (Armuzzi 2013; Savarino 2013). Savarino 2013 re-
ported no conflicts of interest. Armuzzi 2013 reported receiving
educational grants, and consultancy and lecture fees from a phar-
maceutical company. Mowat 2016 was funded by a governmental
grant and adequately reported on conflicts of interest. Funding
and conflict of interest was not reported in two studies (Ardizzone
2004, D’Haens 2008), but our attempt to clarify this by contact-
ing the authors was unsuccessful.
Excluded studies
Eleven studies (15 reports) were excluded for different reasons.
The reasons for exclusion for each study are presented in the
Characteristics of excluded studies table and are summarised be-
low:
• Three studies were not RCTs (Nos 2000; Reinisch 2013;
Robb 2015);
• Six studies assessed the wrong intervention (Ferrante 2015;
Mañosa 2013; NCT01876264; Wright 2014; Wright 2015; Zhu
2015);
• One study was terminated due to slow recruitment
(NCT02247258); and
• One study assessed the wrong population (Vidigal 2014).
Risk of bias in included studies
The risk of bias was assessed as low in one study (Mowat 2016),
high in six studies (Ardizzone 2004; Armuzzi 2013; Herfarth2006;
Lopez-Sanroman 2017; Savarino 2013; Scapa 2015), and unclear
in three (D’Haens 2008; Hanauer 2004; Reinisch 2010). Details
of the risk of bias assessment are presented in the Characteristics
of included studies tables, and in Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
In all of the included studies the allocation of participants to
an active treatment or placebo was reported as random. Eight
studies were judged as being at low risk of bias for random se-
quence generation as these studies employed computer-generated
randomisation (Ardizzone 2004; D’Haens 2008; Hanauer 2004;
Herfarth 2006; Lopez-Sanroman 2017; Mowat 2016; Reinisch
2010; Savarino 2013). Two studies were judged ’unclear’ due to in-
sufficient information on the method of randomisation (Armuzzi
2013; Scapa 2015).
Allocation concealment
In six studies the method of allocation concealment was considered
adequate (Hanauer 2004; Herfarth 2006; D’Haens 2008; Lopez-
Sanroman 2017; Reinisch 2010; Savarino 2013). Four studies were
judged as unclear risk of bias for allocation concealment as the
methods were not adequately described (Ardizzone 2004; Armuzzi
2013; D’Haens 2008; Scapa 2015).
Blinding
Blinding of participants and personnel
Four of the studies included had an open-label study design and
were judged as being at high risk of bias (Ardizzone 2004; Armuzzi
2013; Lopez-Sanroman 2017; Savarino 2013). All the remaining
studies were described as double-blind. The method of blinding
was not adequately described in three studies (D’Haens 2008;
Hanauer 2004; Scapa 2015), thus these studies were marked as
’unclear’. Two of these studies failed to describe whether the
placebo was sufficiently identical to the intervention to blind study
participants (D’Haens 2008; Hanauer 2004), and one study pro-
vided insufficient information to make a judgement (Scapa 2015).
Due to an adequate description of blinding methods, three stud-
ies were assessed as having low risk of performance bias (Herfarth
2006; Mowat 2016; Reinisch 2010).
Blinding of outcome assessment
We assessed one study as having a high risk of detection bias (
Armuzzi 2013). Four studies were marked as ’unclear’ for detection
bias, having failed to adequately describe blinding of outcome
assessors (Ardizzone 2004; Reinisch 2010; Savarino 2013; Scapa
2015). The rest of the studies were judged as having a low risk
of detection bias, for clearly describing the methods regarding
blinding of outcome assessment (D’Haens 2008; Hanauer 2004;
Herfarth 2006; Lopez-Sanroman 2017; Mowat 2016).
Incomplete outcome data
All except two studies reported data fully and documented drop-
outs and reasons for withdrawals. Incomplete outcome data in
these studies was due to study termination (Herfarth 2006), and
failure to report the number of randomised and withdrawn par-
ticipants and reasons for withdrawal (Scapa 2015). The authors of
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Scapa 2015 were contacted for clarification, however no additional
information was provided, except that the study is under prepara-
tion for publication. An ’unclear’ judgment for this domain was
not made for any of the studies.
Selective reporting
Trial registration was available for four studies (Lopez-Sanroman
2017; Mowat 2016; Reinisch 2010; Scapa 2015). Seven studies
were judged as being at low risk of bias for reporting all outcomes
prespecified in the trial registration or in the methods section of
the study manuscript (Ardizzone 2004; Armuzzi 2013; D’Haens
2008; Hanauer 2004; Mowat 2016; Reinisch 2010; Savarino
2013). One study was judged to be ’unclear’ (Herfarth 2006).
Two studies were marked ’high’ for reporting bias: Scapa 2015
failed to report outcomes prespecified in the trial registration and
Lopez-Sanroman 2017 did not adequately report on a prespecified
outcome.
Other potential sources of bias
Eight studies were judged to be at low risk of bias for other ap-
parent sources of potential bias. Two studies provided insufficient
information to enable the reviewers make a judgement and were
rated as ’unclear’ (Herfarth 2006; Scapa 2015).
Effects of interventions
See: Summary of findings for the main comparison
Azathioprine or 6-mercaptopurine compared to placebo for
maintenance of surgically-induced remission in Crohn’s disease;
Summary of findings 2 Azathioprine or 6-mercaptopurine
compared to 5-aminosalicylic acid for maintenance of surgically-
induced remission in Crohn’s disease; Summary of findings 3
Azathioprine or 6-mercaptopurine compared to anti TNF-α for
maintenance of surgically-induced remission in Crohn’s disease
AZA or 6-MP versus placebo
Three studies that compared AZA (100 to 150 mg/day) or 6-MP
in doses of 50 mg/day and 1 mg/kg/day to placebo were identified
(D’Haens 2008; Hanauer 2004; Mowat 2016). In one of these
studies all participants were also taking either metronidazole or
ornidazole (750 mg/day) for the first three months of intervention
(D’Haens 2008).
Primary outcome
Clinical relapse
Three studies reported on clinical relapse, with definitions for clin-
ical relapse varying across studies. D’Haens 2008 defined clinical
relapse as a CDAI > 250. Mowat 2016 defined clinical relapse as
a CDAI > 150 and a 100 point increase in CDAI from baseline.
Hanauer 2004 defined relapse as a clinical reoccurrence grading
score > 2. There was moderate certainty evidence that AZA or 6-
MP are more efficient in preventing clinical relapse than placebo
(Analysis 1.1; Summary of findings for the main comparison). Af-
ter a follow-up of 12 to 36 months, 51% (109/215) of participants
in the AZA/6-MP group relapsed compared to 64% (124/193) of
the placebo group (RR 0.79; 95% CI 0.67 to 0.92; 408 partici-
pants; 3 studies; I² = 0%; GRADE moderate certainty evidence).
The subgroup analysis found no evidence of a difference in clinical
relapse between AZA and 6-MP (P = 0.34). A subgroup analysis
based on length of follow-up found no evidence of a difference in
clinical relapse when measured at 12 months or less or at over 12
months (P = 0.34).
Secondary outcomes
The effect on endoscopic relapse rate as well as the tolerability and
safety of AZA/6-MP agents compared to placebo was uncertain,
due to very low to low certainty evidence (Summary of findings
for the main comparison).
Endoscopic relapse
Endoscopic relapse (Analysis 1.3), defined as endoscopic score i
≥ 2, was reported in two studies (D’Haens 2008; Mowat 2016).
During a follow-up period of 12 to 36 months, 67% (112/168)
of AZA/6-MP participants relapsed endoscopically, compared to
75% (115/153) of placebo participants (RR 0.85; 95% CI 0.64 to
1.13; 321 participants; 2 studies; I² = 62%; GRADE low certainty
evidence). We found no evidence of a difference in endoscopic re-
lapse rates between AZA and 6-MP (P = 0.11). A subgroup analy-
sis based on length of follow-up found no evidence of a difference
in endoscopic relapse rates measured at different times (P = 0.11).
Hanauer 2004 compared endoscopic relapse rates (defined as i ≥
2) between the 6-MP (16%; 95% CI 7% to 35%) and placebo
(42%; 95% CI 21% to 70%) groups at 24 months (HR 0.48;
reported P = 0.13; 87 participants). However, these data were in-
sufficiently reported to be included in the meta-analysis.
Radiologic relapse
Radiologic relapse rate defined as a radiographic recurrence grad-
ing score ≥ 2 was reported in Hanauer 2004. After 24 months,
33% (95% CI, 19% to 54%) of participants treated with 6-MP
had radiologic relapse compared to 49% (95% CI, 30% to 72%)
in the placebo group (HR, 0.61; reported P = 0.19; 84 partici-
pants).
Adverse events, serious adverse events and withdrawal due to
adverse events
There was no clear difference in the number of participants who
experienced adverse events, serious adverse events or withdrawal
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due to adverse events when AZA/6-MP drugs are compared to
placebo. Adverse events (Analysis 1.5) were reported in two studies
( D’Haens 2008; Hanauer 2004). For the follow-up period of 12
to 24 months, 14% (12/87) of AZA/6-MP participants experi-
enced at least one adverse event that was possibly related to treat-
ment compared to 10% (8/81) of the placebo participants (RR
1.36; 95% CI 0.57 to 3.27; 168 participants; 2 studies; I² = 0%;
GRADE low certainty evidence). The subgroup analysis found no
evidence of a difference in adverse events when AZA and 6-MP
were compared (P = 0.32). A subgroup analysis based on length of
follow-up found no evidence of a difference in adverse events when
measured at 12 months or less and over 12 months (P = 0.32).
Commonly reported adverse events included hair loss, leukopenia,
diarrhoea, abdominal pain, hepatotoxicity and arthralgia.
Two studies (Hanauer 2004; Mowat 2016), reported on serious
adverse events (Analysis 1.7), and three studies reported on the
number of withdrawn participants as a result of adverse reactions
to the treatment (D’Haens 2008; Hanauer 2004; Mowat 2016).
About 3% (5/175) of AZA/6-MP participants and 1% (2/152) of
placebo participants experienced serious adverse events during 12
to 36 months of intervention follow-up (RR 1.78; 95% CI 0.39 to
8.18; 327 participants; 2 studies; I² = 0%; GRADE low certainty
evidence). During the same period, almost an equal proportion
of AZA/6-MP (24%; 51/215) and placebo (25%; 49/193) par-
ticipants were withdrawn from the study due to adverse events
(RR 0.90; 95% CI 0.63 to 1.29; 408 participants; 3 studies; I² =
3%; GRADE moderate certainty evidence). A subgroup analysis
found no evidence of a difference in withdrawal due to adverse
events when AZA and 6-MP were compared (P = 0.69). A sub-
group analysis based on length of follow-up found no evidence of
a difference in withdrawals due to adverse events when measured
at 12 months or less or at over 12 months (P = 0.69). Commonly
reported serious adverse events included arthralgia, pancreatitis,
leucopenia and bowel obstruction. Adverse events leading to with-
drawal from the study included abnormal blood results leading to
led to temporary discontinuation of treatment in 28% of the par-
ticipants. However, specific details on reasons for discontinuation
were not clearly reported.
Health related quality of life
HRQoL was reported in one study with no difference in IBDQ
scores between the two treatments group. However these data were
insufficiently reported for inclusion in the analysis (Mowat 2016).
AZA or 6-MP versus 5-ASA
A total of five studies compared the efficacy of AZA (2 to 2.5 mg/
day) or 6-MP (50 mg/day) to mesalamine (dose 3 to 4 g/day)
(Ardizzone 2004; Hanauer 2004; Herfarth 2006; Reinisch 2010;
Savarino 2013). Due to the specific inclusion/exclusion criteria in
Reinisch 2010 (Characteristics of included studies), the clinical
and endoscopic relapse data from this study were not included in
meta-analyses.
Primary outcome
Clinical relapse
Clinical relapse defined as a clinical recurrence grading score ≥
2 (Hanauer 2004; Savarino 2013), or a CDAI ≥ 200 (Ardizzone
2004), was reported in four studies. There was low certainty ev-
idence on the efficacy of AZA or 6-MP for maintaining post-
operative clinical remission in comparison to 5-ASA compounds
(Analysis 2.1; Summary of findings 2). At the end of the 24 month
follow-up, 64% (113/177) of AZA treated participants clinically
relapsed compared to 59% (101/170) of 5-ASA treated ones (RR
1.05, 95% CI 0.89 to 1.24, 347 participants, 4 studies, I² = 8%;
GRADE low certainty evidence). We carried out a subgroup anal-
ysis and found no evidence of a difference in clinical relapse rates
between AZA and 6-MP (P = 0.18). A subgroup analysis based on
length of follow-up found no evidence of a difference in clinical
relapse rates when measured at 12 months or less or at over 12
months (P = 0.97).
Secondary outcomes
Endoscopic relapse
Endoscopic relapse was reported in one study (Savarino 2013),
and was defined as a Rugeerts score ≥ 2. The efficacy of AZA
in comparison to 5-ASA formulations in preventing endoscopic
relapse was uncertain, as the certainty of evidence was very low
(Analysis 2.3; Summary of findings table 2). After 24 months,
65% (11/17) of AZA participants relapsed endoscopically com-
pared to 83% (15/18) of 5-ASA participants (RR 0.78; 95% CI
0.52 to 1.17; 35 participants; 1 study; GRADE very low certainty
evidence).
Radiologic relapse
Radiologic relapse (follow-up 24 months), defined as radiographic
recurrence grading score ≥ 2, was reported in one study (Savarino
2013) and meta-analysis was not performed. There is a very low
certainty evidence regarding the effect of purine analogues on radi-
ologic relapse rate compared to 5-ASA drugs (Analysis 2.4). Sixty-
four percent (13/17) of AZA participants experienced radiologic
relapse compared to 83% (15/18) of 5-ASA participants (RR 0.92;
95% CI 0.66 to 1.28; 35 participants; 1 study; GRADE very low
certainty evidence).
Endoscopic and radiologic relapse rates were reported by Hanauer
2004, however the results were insufficient to be included in the
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meta-analysis. At 24 months (participants 91), reported endo-
scopic and radiologic relapse rates were 16%; 95% CI 7% to 35%
and 33%; 95% CI 19% to 54% in the purine antimetabolites
compared to 48%; 95% CI 30% to 70% and 46%; 95% CI 29%
to 66% in the mesalamine intervention respectively.
Surgical relapse
Surgical relapse (follow-up 24 months), defined as the need for
another surgery was reported in Ardizzone 2004. The effect of
purine analogues compared to 5-ASA for the maintenance of sur-
gical remission was uncertain, because the quality of evidence was
judged as very low (Analysis 2.5; Summary of findings 2). During
the follow-up period of two years, the proportion of participants
with surgical relapse was 37% (26/71) in the 5-ASA group versus
30% (21/71) in the purine analogues group (RR 0.81; 95% CI
0.50 to 1.29; 142 participants; 1 study; GRADE very low cer-
tainty evidence).
Adverse events, serious adverse events and withdrawal due to
adverse events
Adverse events and withdrawal due to adverse events were re-
ported in four studies (Ardizzone 2004; Hanauer 2004; Reinisch
2010; Savarino 2013), and five studies respectively (Ardizzone
2004; Hanauer 2004; Herfarth 2006; Reinisch 2010; Savarino
2013), while serious adverse events were reported in three stud-
ies (Ardizzone 2004; Hanauer 2004; Reinisch 2010). The effect
of purine analogues when compared to 5-ASA drugs on adverse
events was uncertain, as the quality of evidence was low (Summary
of findings 2). During a follow-up of 12 to 24 months, the pro-
portion of participants who experienced at least one adverse event
(Analysis 2.6) was 41% (73/176) and 48% (81/170) in the AZA/
6-MP and 5-ASA groups respectively (RR 0.89; 95% CI 0.74 to
1.07; 346 participants; 4 studies; I² = 15%; GRADE low certainty
evidence). We found no evidence of a difference in adverse events
when we carried out a subgroup analysis comparing AZA to 6-
MP (P = 0.34). A subgroup analysis based on length of follow-
up found no evidence of a difference in adverse events when mea-
sured at 12 months or less or at over 12 months (P = 0.66). Com-
monly reported adverse events included leukopenia, abdominal
pain, nausea, nasopharyngitis, diarrhoea. and headache. During a
12 to 24 months follow-up, serious adverse events (Analysis 2.8)
were experienced by 17% (27/159) of purine analogue participants
compared to 4% (6/152) of 5-ASA participants (RR 3.39; 95%
CI 1.26 to 9.13; 311 participants; 3 studies; I² = 9%; GRADE
very low certainty evidence). We found no evidence of a differ-
ence in serious adverse events when we carried out a subgroup
comparing AZA to 6-MP (P = 1.0). A subgroup analysis based
on length of follow-up found no evidence of a difference in se-
rious adverse events when measured at 12 months or less or at
over 12 months (P = 0.19). Commonly reported serious adverse
events include postoperative bowel obstruction. The proportion
of participants that withdrew from the trial due to an adverse event
(Analysis 2.10) during 12 to 24 months follow-up were 19% (42/
218) versus 8% (16/207) in the AZA/6-MP and 5-ASA groups
respectively (RR 2.21, 95% CI 1.28 to 3.81; participants = 425;
studies = 5; I² = 0%; GRADE low certainty evidence). We found
no evidence of a difference in withdrawals due to adverse event
when AZA and 6-MP were compared (P = 0.25). A subgroup anal-
ysis based on length of follow-up found no evidence of a difference
in withdrawal due to adverse events when measured at 12 months
or less or at over 12 months (P = 0.46). Adverse events leading to
withdrawal included severe epigastric intolerance, increase in liver
function test results, leukopenia and acute pancreatitis.
HRQoL
Two studies with a follow-up of 12 to 24 months reported on
HRQoL based on the IBDQ score (Reinisch 2010; Savarino
2013). The effect of 5-ASA agents on HRQoL was uncertain as a
result of serious limitations due to unclear risk of performance and
outcome assessment bias and high risk of performance bias and
outcome assessment bias in each study respectively and very seri-
ous limitations due to sparse data in both studies. Savarino 2013
reported on the proportion of participants with an IBDQ score >
170 (ranging from 32 to 224), which is regarded as a symptomatic
remission score (Analysis 2.12). After 24 months of follow-up,
12% (2/17) of AZA treated participants reported an IBDQ score
>170 compared with 17% (3/18) of 5-ASA participants (RR 0.71;
95% CI 0.13 to 3.72; 35 participants; 1 study; GRADE very low
certainty evidence). Reinisch 2010, assessed HRQoL based on
the mean change of IBDQ scores compared to baseline (Analysis
2.13.) At 12 months, the mean IBDQ difference compared to
baseline was 9 (SD 17.7) in the AZA group versus 5 (SD 27.4) in
the 5-ASA treated group (MD 4; CI 14.36 to -6.36; 78 partici-
pants; 1 study; GRADE very low certainty evidence).
AZA or 6-MP versus anti-TNF-α
Three studies comparing AZA to either infliximab (Armuzzi
2013), or adalimumab (Lopez-Sanroman 2017; Savarino 2013),
and one study comparing 6-mercaptopurine to adalimumab
(Scapa 2015), were identified. For all of the studies, the interven-
tion started within 45 days of surgery. In the Lopez-Sanroman
2017 study all participants were also administered metronidazole
(750 mg/day) for the first three months of the study. The total
number of assessed participants was 157.
Primary outcome
Clinical relapse
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Clinical relapse (Analysis 3.1) was reported in three studies
(Armuzzi 2013; Lopez-Sanroman 2017; Savarino 2013), and was
defined as HBI ≥ 2 (Armuzzi 2013), clinical recurrence grading
score ≥2 (Savarino 2013) or CDAI score >200 (Lopez-Sanroman
2017). The certainty of evidence that AZA is inferior in preventing
postsurgical clinical relapse compared to anti-TNF-α agents was
very low (Summary of findings 3). During a follow-up of 12 to 24
months, 43% (29/67) of participants treated with AZA clinically
relapsed compared to 14% (10/72) of participants in the anti-
TNF-α group (RR 2.89, 95% CI 1.50 to 5.57, 139 participants,
3 studies, I² = 0%; GRADE very low certainty evidence). The
subgroup analysis based on length of follow-up found no evidence
of a difference in clinical relapse when measured at 12 months or
less or at over 12 months (P = 0.2).
Secondary outcomes
Endoscopic relapse
Endoscopic relapse was reported in four studies and was defined
as Rutgeerts score ≥2. The evidence that purine antimetabolites
are less efficient than anti-TNF-α for maintaining endoscopic re-
mission was very low (Analysis 3.3; Summary of findings 3). The
proportion of purine analogue participants with endoscopic re-
lapse was 58% (43/74) compared to 26% (22/83) of anti-TNF-α
participants (RR 3.67; 95% CI 1.05 to 12.81; 157 participants;
4 studies; I² = 64%; GRADE very low certainty evidence). We
found no evidence of a difference in endoscopic relapse rates when
we carried out a subgroup analysis to compare AZA to 6-MP (P
= 0.72). A subgroup analysis based on length of follow-up found
a quantitative difference in endoscopic relapse when measured at
12 months or less or at over 12 months (P = 0.2).
Radiologic relapse
Radiologic relapse was reported in two studies, defined either as
radiographic recurrence grading score ≥ 2 (Savarino 2013), or
based on magnetic resonance enterography scores MR2 and MR3
(Lopez-Sanroman 2017). The certainty of evidence that purine
analogues are less efficient to prevent endoscopic relapse than
adalimumab or infliximab was very low (Analysis 3.5; Summary
of findings 3). The proportion of participants with endoscopic
relapse after 12 to 24 months follow-up was 69% (39/56) and
38% (23/61) among the purine analogues and anti-TNF-α treated
groups respectively. Data pooling for Savarino 2013 (RR 1.36,
95% CI 0.94 to 1.98) and Lopez-Sanroman 2017 (RR 12.24,
95% CI 1.8 to 83.12) was not feasible due to considerable hetero-
geneity (I² = 85%). The certainty of evidence was rated very low
due to high risk of bias and very serious imprecision.
Histologic relapse
Histologic relapse (Analysis 3.6), based on the scoring system mod-
ified by Regueiro 2009 was reported only in Armuzzi 2013 and
a meta-analysis was not performed. Histologic relapse during 12
months of follow-up was detected in 82% (9/11) and 18% (2/11)
participants of the AZA and infliximab groups respectively (RR
4.50; 95% CI 1.25 to 16.25).
Adverse events, serious adverse events and withdrawal due to
adverse events
Adverse events were reported in two studies (Lopez-Sanroman
2017; Savarino 2013). Withdrawals due to adverse events were
reported in three studies ( Armuzzi 2013; Lopez-Sanroman 2017;
Savarino 2013), and serious adverse events were reported in one
study (Lopez-Sanroman 2017). The certainty of evidence regard-
ing tolerability and safety of purine analogues in comparison to
anti-TNF-α agents ranged from very low to low (Summary of
findings 3). There was no clear difference in the number of par-
ticipants who experienced adverse events when AZA/6-MP was
compared to anti-TNF-α during the follow-up of 12 to 24 months
(Analysis 3.7). Fifty-seven per cent (32/56) of AZA/6-MP partici-
pants experienced at least one adverse event compared to 51% (31/
61) of the anti-TNF-α group (RR 1.13; 95% CI 0.83 to 1.53; 117
participants; 2 studies; I² = 0%; GRADE low certainty evidence). A
subgroup analysis based on length of follow-up found no evidence
of a difference in adverse events when measured at 12 months or
less or at over 12 months (P = 0.65). Commonly reported ad-
verse events included bronchitis, nasopharyngitis, arthralgia, nau-
sea and abscess (Savarino 2013). Full details concerning adverse
events were not reported in Lopez-Sanroman 2017. The evidence
regarding serious adverse events comes from a single study and a
meta-analysis was not performed (Analysis 3.9). The proportion
of participants with serious adverse events was 10% (4/39) and
20% (9/45) among the AZA and adalimumab groups respectively
(RR 0.51; 95% CI 0.17 to 1.54; 84 participants; 1 study; GRADE
very low certainty evidence). The types of serious adverse events
were not described. Over a follow-up that ranged from 12 to 24
months, 16% (11/67) of AZA/6-MP treated participants were
withdrawn from the study due to an adverse event compared to
3% (2/72) of the anti-TNF-α treated participants (RR 3.97; 95%
CI 0.92 to 17.22; 139 participants; 3 studies; I² = 4%; GRADE
low certainty evidence). A subgroup analysis based on length of
follow-up found no evidence of a difference in withdrawals due
to adverse events when measured at 12 months or less or at over
12 months (P = 0.24). Adverse events leading to withdrawal in-
cluded severe nausea, leukopenia, arthralgia, urothelial carcinoma,
dyspepsia, dyspnoea, death, atopic dermatitis and abdominal pain
with increase in pancreatic enzymes.
Health related quality of life
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A single study assessed health-related quality of life (Savarino
2013). At 24 months, an IBDQ > 170 was recorded in 12% (2/17)
of participants treated with AZA compared to 88% (14/16) treated
with adalimumab (RR 0.13; 95% CI 0.04 to 0.50; 34 participants;
1 study). This outcome was also evaluated in Lopez-Sanroman
2017 using the EuroQol-5 dimensions questionnaire, however
reported data were insufficient to be included in meta-analysis.
Special safety note
It is worth specifically noting that two adverse events leading to
therapy cessation occurred in more than 1% of participants treated
with purine analogues. Pancreatitis was a serious adverse event
that led to withdrawal across several of the studies. However, the
rate of occurrence was almost exclusively in participants receiving
purine analogues (11 cases in 354 participants taking purine ana-
logues, 3.1%) compared to no occurrences in any of the compar-
ison groups (i.e. placebo, 5-ASA or anti-TNF-α) in this review.
Leucopenia occurred also almost exclusively in participants receiv-
ing purine analogues (9 cases in 354 participants, 2.5%) compared
to no occurrences in all other groups.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Azathioprine or 6-mercaptopurine compared to 5-aminosalicylic acid for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: People with surgically-induced remission in Crohn’s disease
Setting: Outpat ient
Intervention: Azathioprine (2 mg/ kg/ day) or 6-mercaptopurine (50 mg/ day)
Comparison: 5-aminosalicylic acid
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with 5-aminosali-
cylic acid
Risk with Azathioprine
or 6-mercaptopurine
Clinical relapse
Follow-up: 12 to 24
months
Study populat ion RR 1.05 (0.89, 1.24) 347
(4 RCTs)
⊕⊕©©
LOW 12
Clinical relapse def ined
as a clinical grading
score ≥ 2 (Hanauer
2004;Savarino 2013)
or CDAI ≥ 200 (
Ardizzone 2004)
556 per 1,000 595 per 1,000
(456 to 773)
Endoscopic relapse
Follow-up: 24 months
Study populat ion RR 0.78
(0.52 to 1.17)
35
(1 RCT)
⊕©©©
VERY LOW 13
Endoscopic relapse de-
f ined as a Rugeerts
score ≥ 2 (Savarino
2013)
833 per 1,000 650 per 1,000
(433 to 975)
Radiologic relapse
Follow-up: 24 months
Study populat ion RR 0.92
(0.66 to 1.28)
35
(1 RCT)
⊕©©©
VERY LOW 14
Radiologic relapse de-
f ined as a radiographic
grading score ≥ 2 (
Savarino 2013)
833 per 1,000 767 per 1,000
(550 to 1,000)
Surgical relapse
Follow-up: 24 months
Study populat ion RR 0.81
(0.50 to 1.29)
142
(1 RCT)
⊕©©©
VERY LOW 15
Surgical relapse de-
f ined as a need
for another surgery (
Ardizzone 2004)
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366 per 1,000 297 per 1,000
(183 to 472)
Adverse events
Follow-up: 12 to 24
months
Study populat ion RR 0.89
(0.74 to 1.07)
346
(4 RCTs)
⊕⊕©©
LOW 16
Re-
ported adverse events
include leukopenia, ab-
dominal pain, nausea,
nasopharyngit is, diar-
rhoea. and headache
476 per 1,000 424 per 1,000
(353 to 510)
Serious adverse events
Follow-up: 12 to 24
months
Study populat ion RR 3.39
(1.26 to 9.13)
311
(3 RCTs)
⊕©©©
VERY LOW 17
Reported serious ad-
verse events include
postoperat ive bowel
obstruct ion
39 per 1,000 134 per 1,000
(50 to 360)
Withdrawal due to ad-
verse events
Follow-up: 12 to 24
months
Study populat ion RR 2.21 (1.28, 3.81) 425
(4 RCTs)
⊕⊕©©
LOW 18
Adverse events lead-
ing to withdrawal in-
clude Severe epigastric
intolerance, increase in
liver funct ion test re-
sults, leukopenia, acute
pancreat it is
76 per 1,000 172 per 1,000
(93 to 317)
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high risk of bias
2 Downgraded one level due to serious imprecision (214 events) and 95% CI which includes no ef fect and appreciable harm
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3 Downgraded two levels due to very serious imprecision (26 events) and 95% CI which includes no ef fect and appreciable
benef it
4 Downgraded two levels due to very serious imprecision (28 events) and 95% CI which includes no ef fect and appreciable
benef it
5 Downgraded two levels due to very serious imprecision (47 events) and 95%CI which includes appreciable benef it and harm
6 Downgraded one level due to serious imprecision (154 events) and 95%CI which includes no ef fect and appreciable benef it
7 Downgraded two levels due to serious imprecision (33 events)
8 Downgraded one level due to serious imprecision (58 events)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Azathioprine or 6-mercaptopurine compared to anti-TNF-α for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: People with surgically-induced remission in Crohn’s disease
Setting: Outpat ient
Intervention: Azathioprine (2-2.5 mg/ kg/ day) or 6-mercaptopurine (1.5 mg/ kg/ day)
Comparison:Anti-TNF-α
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with anti- TNF-α Risk with Azathioprine
or 6-mercaptopurine
Clinical relapse
Follow-up: 12 to 24
months
Study populat ion RR 2.89
(1.50 to 5.57)
139
(3 RCTs)
⊕⊕©©
VERY LOW 12
Clinical relapse def ined
as: an HBI ≥2 (Armuzzi
2013), a clinical recur-
rence grading score ≥2
(Savarino 2013)
or a CDAI score >200 (
Lopez-Sanroman 2017)
139 per 1,000 401 per 1,000
(208 to 774)
Endo-
scopic relapse Follow-
up: 12 to 24 months
Study populat ion RR 3.67
(1.05 to 12.81)
157
(4 RCTs)
⊕©©©
VERY LOW 134
Endoscopic relapse de-
f ined as a Rugeerts
score ≥ 2 (Armuzzi
2013; Lopez-Sanroman
2017; Savarino 2013;
Scapa 2015)
265 per 1,000 973 per 1,000
(278 to 1,000)
Radiologic relapse
Follow-up: 12 to 24
months
Study populat ion - 117
(2 RCTs)
- Radiologic relapse de-
f ined as a radiographic
grading score ≥ 2 (
Savarino 2013) or mag-
net ic resonance en-
terography score ≥2 (
Lopez-Sanroman 2017)
* due to considerable
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heterogeneity (I² = 85%)
, data pooling was not
feasible. It is uncer-
tain whether azathio-
prine leads to a dif fer-
ence in radiologic re-
lapse when compared
to inf liximab as the cer-
tainty of the evidence is
very low (RR1.36, 95%
CI 0.94 to 1.98; RR 12.
24, 95%CI 1.8 to 83.12)see comment see comment
Surgical relapse Outcome not reported Not reported
Adverse events
Follow-up: 12 to 24
months
Study populat ion RR 1.13
(0.83 to 1.53)
117
(2 RCTs)
⊕⊕©©
LOW 15
Adverse events include
bronchit is, nasopharyn-
git is, arthralgia, nau-
sea, abscess were re-
ported in Savarino
2013. Full details were
not reported in Lopez-
Sanroman 2017
508 per 1,000 574 per 1,000
(422 to 778)
Serious adverse events
Follow-up: 12 months
Study populat ion RR 0.51
(0.17 to 1.54)
84
(1 RCT)
⊕©©©
VERY LOW 16
Serious adverse events
not reported
200 per 1,000 102 per 1,000
(34 to 308)
Withdrawal due to ad-
verse events
Follow-up: 12 to 24
months
Study populat ion RR 3.97
(0.92 to 17.22)
139
(3 RCTs)
⊕⊕©©
LOW 16
Adverse events lead-
ing to withdrawal in-
cluded severe nau-
sea, leukopenia, arthral-
gia, urothelial carci-
noma, dyspepsia, dysp-
noea, death, atopic der-
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matit is and abdominal
pain with increase in
pancreat ic enzymes
28 per 1,000 110 per 1,000
(26 to 478)
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high risk of bias
2 Downgraded two levels due to very serious imprecision (39 events)
3 Downgraded one level due to serious imprecision (65 events)
4 Downgraded one level due to substant ial heterogeneity (I² = 64%)
5 Downgraded one level due to serious imprecision (63 events)
6 Downgraded two levels due to very serious imprecision (13 events)
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D I S C U S S I O N
Summary of main results
Ten RCTs assessing the effectiveness of AZA and 6-MP for main-
taining surgically-induced remission in Crohn’s disease were stud-
ied. The studies recruited people with Crohn’s disease over the age
of 16 years who were in surgically-induced remission. The partic-
ipants were randomised after surgery to received AZA or 6-MP,
placebo, 5-ASA agents or anti-TNF-α agents.
We found moderate certainty evidence that AZA and 6-MP are
superior to placebo for preventing post-surgical clinical relapse in
Crohn’s disease. There was low certainty evidence on the safety of
AZA and 6-MP when adverse events and serious adverse events
were considered. The certainty of the evidence for withdrawal
due to adverse events was moderate. This was due to imprecision
resulting from very sparse data.
There was no clear difference clinical relapse when AZA or 6-MP
was compared with 5-ASA. There are considerable concerns raised
with the safety profile of AZA and 6-MP. For the safety outcome
serious adverse events and withdrawals due to adverse events, 5-
ASA was found to be superior to AZA and 6-MP. However, the
certainty of evidence for the efficacy and safety outcomes were low
due to high risk of performance bias and sparse data.
There was very low certainty evidence that AZA and 6-MP may
be inferior to anti-TNF-α agents for preventing clinical relapse.
We also found no clear difference in adverse events, serious adverse
events or withdrawals due to adverse events when both outcomes
were compared. This was also based on low certainty evidence.
The evidence was downgraded due to high risk of performance
bias and sparse data, therefore, the results should be interpreted
with caution.
Overall completeness and applicability of
evidence
We consider the evidence from this review to be applicable to
most patients with post-surgical remission of Crohn’s disease. The
evidence only assesses AZA or 6-MP compared with placebo, 5-
ASA or anti-TNF-α agents. All outcomes which we had aimed
to analyse were reported in the studies. However, other measures
of relapse (endoscopic, histologic and surgical) and health related
quality of life were sparsely reported. This meant that very little
data were available for our analysis. The review found moderate
certainty evidence on the efficacy of AZA and 6-MP compared
with placebo. This can be considered complete and not requir-
ing new studies, however, the evidence comparing it with 5-ASA
and anti-TNF-α were of very low or low certainty. Therefore,
additional studies may change the results. The use of concomi-
tant treatments such as antidiarrhoeal agents, corticosteroids and
antibiotics were reported in some studies. The circumstances in
which these treatments were given were noted in the studies and
judged to be reflective of clinical practice.
Quality of the evidence
The certainty of the evidence was rated very low to moderate.
Overall, six studies were at high risk of bias and three were at
unclear risk of bias. Downgrading for limitations was mostly due
to lack of blinding and this was particularly common with the head
to head comparisons of active drugs. For most of the outcomes,
there was imprecision due to sparse data as the number of events
ranged between seven and 154. For the clinical relapse outcome,
the optimal information size was obtained from power calculations
in the largest and most recent study (Mowat 2016). Most of the
results were consistent except in two instances where there was
substantial statistical heterogeneity (I² between 62% and 64%).
There was no indirectness as all the studies in the review met the
criteria proposed in the scope of the review. We were unable to
assess for publication bias due to insufficient data.
Potential biases in the review process
We attempted to reduce potential biases in the review process.
A comprehensive literature search was performed to identify all
eligible studies. Two review authors independently assessed studies
for inclusion, extracted data and assessed study quality.
All analyses were completed using the intention-to-treat principle,
whereby participants with final missing outcomes were assumed to
have relapsed. Given the high attrition rate in the purine analogue
groups compared to the 5-ASA groups, this may have affected the
difference in clinical relapse rates between purine analogues and 5-
ASA. However, it is arguably a moot point given that even if purine
analogues did have superior efficacy, it is difficult to rationalise the
use on the basis of the poor adverse event profile in the published
evidence.
One of the included studies administered active concomitant treat-
ments in both intervention arms. This was considered a source of
clinical heterogeneity in analyses that included studies which had
no concomitant treatments. We did not remove this study from
the analyses as a sensitivity analysis showed no difference in the
results.
Agreements and disagreements with other
studies or reviews
A recent Cochrane review assessing the use of AZA or 6-MP for
maintenance of medically-induced remission in Crohn’s disease
revealed that the purine analogues are more effective than placebo,
with higher response rates for AZA than 6-MP (Chande 2015).
These findings are mirrored in the four studies comparing purine
analogues to placebo. No difference in efficacy was found between
28Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease (Review)
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AZA or 6-MP and 5-ASA. This could be due to lower disease
activity following resection of the gut than is achieved in medi-
cally-induced remission of Crohn’s disease, so that a milder anti-
inflammatory agent such as 5-ASA, gives a better risk versus bene-
fit ratio when compared to AZA and 6-MP. It is also possible that
the methodology of the included studies supports this hypothesis,
with all but one study recruiting participants in the immediate
post-surgical setting. As such, the participants are potentially at
their lowest period of disease activity clinically and microscopi-
cally. The findings regarding safety are also consistent with the two
most common adverse events noted as pancreatitis and leucope-
nia.
A Cochrane review looking at the use of 5-ASA for the mainte-
nance of surgically-induced remission in Crohn’s disease suggests
that 5-ASA may be superior to placebo (Gjuladin-Hellon 2019).
It also suggested that 5-ASA is a safe and well-tolerated drug, as
the incidence of adverse events was not different in participants
receiving 5-ASA compared to those receiving placebo. The results
of this systematic review question the risk versus benefit balance
of starting a purine analogue over 5-ASA in postoperative Crohn’s
disease.
The international guidance from the European Crohn’s and coli-
tis Organisation (ECCO) updated in 2016 is consistent with the
findings of this review in that they do indicate a role for purine
analogues (Gionchetti 2016), although they do not comment on
the limitations of the evidence as identified in this review. Most
importantly, the significant safety questions raised in the synthe-
sis performed in this review are not discussed within the ECCO
documents in this context (section 8G), although leucopenia is
noted in medical induced remission maintenance (6E). The Na-
tional Insitutue for Clinical and Care Excellence (NICE) in the
UK suggests AZA as first line therapy in this context (NICE 2016),
citing the previous version of this review in their 2016 guidance
(Gordon 2014). Unlike ECCO, the NICE guidance makes no spe-
cific mention of safety concerns. Given one of the specific adverse
events noted frequently (leucopenia) is recognised in the context
of purine analogues, it is important to highlight that the risk of
pancreatitis has not been highlighted in either guideline, despite
being recognised as the most common serious adverse events in
both Cochrane reviews on these medications.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate certainty evidence suggests that purine analogues may
be superior to placebo for maintenance of surgically-induced re-
mission in participants with Crohn’s disease. There was no clear
difference in the number of clinical relapses when purine ana-
logues were compared with 5-ASA agents, however this is based
on low certainty evidence and no firm conclusions can be drawn.
However, participants taking purine analogues were more likely
than 5-ASA participants to experience serious adverse events and
discontinue therapy due to adverse events. Very low certainty evi-
dence suggests that AZA and 6-MP may be inferior to anti-TNF-
α agents, however, no firm conclusions can be drawn.
Implications for research
Further research investigating the efficacy and safety of AZA and
6-MP in comparison to other active medications in surgically-
induced remission of Crohn’s disease is warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ardizzone 2004
Methods Study design: RCT, single centre
Setting: University “L.Sacco” Hospital (Milan, Italy), 1994 to 2001
Participants Inclusion:
Adult (18 to 70 years) participants who underwent surgery for symptomatic intestinal
stenosis or occlusion, which is clinically quiescent (CDAI ≤ 150) able to start oral
nutrition and oral medication within the first 2 postoperative weeks
Exclusion: Contraindications for use of mesalamine or AZA and pre-existing hepatic dis-
ease, renal dysfunction, clinically important lung disease, systemic infection, short-bowel
syndrome, presence of alcoholic stoma, history of cancer, hypersensitivity to mesalamine
or AZA, erythrocyte macrocytosis, use of immunosuppressive drugs in the past 3 months;
participants who had received treatment with anti-TNF-α within the 6 months before
surgery; pregnancy/breastfeeding; participants who had undergone surgical procedures
other than conservative surgery or for perianal disease only; history of corticosteroid-
dependent disease
Age (IG1 / IG2) mean: 38.4 years
Sex (M:F): 95: 52 overall; (45:26) versus (50:26)
Type of surgery: Stricturoplasty- 36; Minimal bowel resection- 70; Minimal bowel
resection stricturoplasty-36
Previous surgery (IG1+IG2): 69/142 overall (38/71) versus (31/71)
Start of intervention after surgery: < 2 weeks
Medication use (IG1+ IG2): Mesalamine or sulphasalazine 62; Corticosteroids 41;
Immunosuppressants 9; None 30
Smoker (IG1 / IG2): (28/71) versus (36/71)
Number randomised (N = 142): 71 versus 71
Number analysed (N = 138): (69/71) versus (69/71) - ITT; 50/71 versus 61/71 - per
protocol
Post-randomisation exclusion (n = 11): (6/71) versus (5/71) (did not start the treatment
-3 (2 versus 1); lost to follow-up -8 (4 versus 4))
Interventions Group 1: Azathioprine administered at a dosage of 2 mg/kg/day
Group 2: Mesalamine was administered at a dosage of 3 g/day divided into 3 doses
All participants: treatment with aminosalicylates, metronidazole, and any other CD-
specific treatment had to be discontinued. Corticosteroids were allowed to be tapered by
standardized stepwise dose reductions within 6 weeks after surgery at the latest. Symp-
tomatic treatment with antacids, antidiarrhoeal agents, or spasmolytic agents was allowed
but had to be scrupulously recorded. Compliance with treatment was evaluated by a
simple questionnaire in which adverse events were also recorded. Participants receiving
AZA were regularly assessed by total blood cell count and serum transaminase values to
monitor any myelotoxicity and hepatotoxicity of the treatment. Participants were seen
at baseline and every 6 months
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Ardizzone 2004 (Continued)
Outcomes Duration of study: 24 months
1. Clinical relapse defined as the presence of symptoms related to CD, variably associated
with radiologic, endoscopic, and laboratory findings, with a CDAI score > 200, which
is considered severe enough to warrant treatment with a systemic corticosteroid at a
medium-high dose
2. Surgical Relapse defined as the presence of symptoms refractory to medical treatment
or complications requiring another surgical procedure (e.g., occlusive disease, intra-
abdominal abscesses, or high-flow fistulas)
3. Adverse events
Notes Funding source: Not reported
Conflict of interest: Not reported
Power calculation: Based on a maximum relapse rate at 2 years of 45% mesalamine,
62 participants per treatment group was considered sufficient to detect a difference of ≥
25% for the AZA treatment group (type 1 error of 5%). The number of participants in
each group was increased to 68 to compensate for an anticipated drop out rate of 10%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After surgery, patients who met the
inclusion criteria and who agreed to en-
ter the study were randomised to receive
mesalamine or AZA by a computer-gen-
erated list” and ”Randomization was per-
formed in blocks of 10”
Comment: computer generated block ran-
domisation
Allocation concealment (selection bias) Unclear risk Insufficient information to make judgment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the study is open-label and
blinding was not performed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to make judg-
ment, however it is unlikely
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotes: “In the intention-to-treat analy-
sis, all randomised patients who received at
least one dose of the study drug and were
subjected to the baseline evaluation were
considered for the analysis.”and “Outcome
measures were analysed in all randomised
patients who had taken at least one dose
of the study medication (intention-to-treat
population)…”
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Ardizzone 2004 (Continued)
Comment: ITT analysis applied, all with-
drawals were low and balanced across
groups
Selective reporting (reporting bias) Low risk Trial registration not available, however all
outcomes stated in the method section as-
sessed and reported
Other bias Low risk Quote: “No significant differences were ob-
served between the 2 treatment groups re-
garding age, sex, duration of disease, lo-
cation of disease, fistula and abscess at
surgery, surgical procedure, previous oper-
ations, and CD therapy during the previ-
ous 6 months”
Comment: baseline characteristics well bal-
anced across groups
Armuzzi 2013
Methods Study design: RCT, single centre
Setting: Italy, 2007 to 2011
Participants Inclusion: Consecutive CD participants who underwent curative ileocolonic resection
(all macroscopically inflamed tissues were removed and operative margins were disease-
free at histopathology examination) and considered at “high risk”* of postoperative
recurrence
were enrolled
Exclusion: active perianal disease, presence of stoma, adverse events during previous
therapy with infliximab or azathioprine, age > 70 years, surgical complications, active
infectious diseases, history of cancer, renal, cardiac or hepatic failure, history of acute or
chronic pancreatitis, severe leucopenia (WBC <3000 µu/ml, lymphocyte count <1000
µu/ml) and pregnancy
Age (IG1 / IG2) median (range): 32 years (18 to 70 years)
Sex (M:F): 15:7 overall; (7:4) versus (8:3)
Type of surgery: Not reported
Previous surgery (IG1+IG2): Not reported
Start of intervention after surgery: 2 to 4 weeks
Medication use (IG1+ IG2): Previous treatment with AZA-5; previous treatment with
INF -10
Smoker (IG1 / IG2): Not reported
Number randomised (N = 22): 11/11
Number analysed (N = 22): (11/11) versus (11/11)
Post-randomisation exclusion (n = 0)
Interventions Group 1: Infliximab (5 mg/kg)at 0, 2 and 6 week and then every 8 weeks for 1 year
Group 2: Azathioprine (2.5 mg/kg/day) for 1 year
All participants: All participants also received oral metronidazole (500 mg twice daily)
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Armuzzi 2013 (Continued)
for 2 weeks after surgery. No other CD-related drugs were admitted during the study.
Participants were monthly evaluated, according to laboratory tests, the Harvey-Bradshaw
Index (HBI) calculation and the adverse event report
Outcomes Duration of study: 12 months and follow-up at 40 months
1. Clinical recurrence defined by a HBI ≥ 8
2. Endoscopic recurrence defined by a Rutgeerts’ score ≥ i2 at 12 months and 40
months (follow-up)
3. Histologic activity score based on a Histology Score System modified from Regueiro
et al
4. Adverse events
Notes Funding source: Not reported
Conflict of interest: Authors declare the following conflict of interest: AA received: con-
sultancy from Abbvie, MSD; lecture fees fromAbbvie, MSD, Chiesi, Ferring, Nycomed,
Otsuka; educational grants from Abbvie, MSD, Ferring, Nycomed. LG received: edu-
cational grants from Abbvie, MSD. CF, AP, MM, DP, GA, FF, IDV, GLR: nothing to
declare
Power calculation: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomised with a
simple unblinded 1:1 allocation ratio to re-
ceive…”
Comment: simple randomisation per-
formed, however insufficient information
on the method of randomisation used
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “One unblinded endoscopist (AP)
did all the examinations and calculated
scores. Two further unblinded endoscopists
(IDV and GA) separately reviewed videos
and in case of discordance a consensus
agreement was reached among the three op-
erators”
Comment: blinding of outcome assessors
not performed
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Armuzzi 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One patient did not tolerate aza-
thioprine because of severe nausea with epi-
gastric pain and withdrew from the study
after 5 weeks of treatment”
Comment: only one patient withdrew from
the study and reason described
Selective reporting (reporting bias) Low risk Trial registration not available, however all
outcome data stated in the method section
were reported
Other bias Low risk Groups well balanced at baseline and no
other apparent sources of bias detected
D’Haens 2008
Methods Study design: RCT, multicentre
Setting: Belgium / University Hospital Leuven and Imelda General Hospital, Bonheiden;
1999 to 2005
Participants Inclusion: Adult participants (18 to 70 years) who underwent curative ileal or ileocolonic
resection with ileocolonic anastomosis for CD with a presence of 1 risk factor for the
development of early/severe postoperative recurrence of their CD. Participants had to
understand and sign a written informed consent form. Women of childbearing age
needed to have a negative pregnancy test and had to use adequate birth control measures
during the whole study
Exclusion: Presence of macroscopic evidence for CD proximally or distally to the site of
resection or the presence of frank pancolitis or an ileorectal anastomosis (ileosigmoidal
anastomosis was allowed); participants with a stoma; operation for fibrostenosis only,
without evidence of inflammatory activity on histology; former intolerance to metron-
idazole and/or AZA; who wished to become pregnant; low white blood cell count at
inclusion (4000); alcohol or drug abuse; participants who had used AZA in the 2 months
before surgery; participants with malignancies and/or ongoing infectious disease (hep-
atitis, tuberculosis, AIDS) with the exception of herpes simplex infection. Former use of
biologicals was not permitted
Age (IG1 / IG2) mean: 38.8 years (22 to 67 years) versus 40.0 years (21 to 69 years);
overall age not reported
Sex (M:F): 44:37 overall; (24:16) versus (20:21)
Type of surgery: Not reported
Previous surgery (IG1+IG2):Second surgery-20 (12/8); third surgery-3 (2/1)
Start of intervention after surgery: ≤ 2 weeks
Medication use (IG1+ IG2): AZA past use: 5 (3/2); Steroid use at surgery: 21 (12/9)
Smoker (IG1 / IG2): (13/40) versus (17/41)
Number randomised (N = 81): 40/41
Number analysed (N = 81): (40/40) versus (41/41)
Post-randomisation exclusion (n = 5): (3/40) versus (2/41) (Withdrawal of consent-5
(3/2)
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D’Haens 2008 (Continued)
Interventions Group 1: 3 months of metronidazole therapy at a dose of 250 mg 3 times per day
plus AZA depending on body weight. AZA only for the rest of the study. Participants
whose body weight was 60 kg received 2 tablets of AZA (100 mg), whereas participants
weighing 60 kg received 3 tablets or 150 mg AZA
Group 2: 3 months of metronidazole therapy at a dose of 250 mg 3 times per day plus
placebo. Placebo only for the rest of the study
All participants: Participants intolerant to metronidazole were switched to ornidazole
500 mg twice per day orally. All concomitant anti-inflammatory medications were dis-
continued, except for glucocorticosteroids, which were gradually tapered over 6 weeks
after surgery. Antibiotics were allowed during the study for concurrent infections, but
not for CD. Topical therapy for perianal CD could be continued if necessary. Cholestyra-
mine was allowed for the treatment of bile acid diarrhoea. Participantswere instructed
to take their other drugs at least 1 hour after the intake of cholestyramine. Participants
underwent clinical evaluation with physical examination and biochemical analysis at
baseline and weeks 2, 6, 12, 20, 28, 36, 44, and 52 after randomisation. At week 12
and 52, participants underwent an ileocolonoscopy. Adverse events and concomitant
medication were recorded at every scheduled or unscheduled visit.
Outcomes Duration of study: 12 months
1. Endoscopic recurrence in the neoterminal ileum defined as an endoscopic index ≥
2 according to Rutgeerts’ endoscopic score
2. Clinical recurrence defined as CDAI > 250
3. Adverse events
4.Withdrawal due to adverse events
Notes Funding source: Not reported
Conflict of interest: Not reported
Power calculation: It was estimated on the basis of prior recurrence-prevention studies,
that 50-55% of the participants in the placebo group would have endoscopic recurrence
at 1 year. Assuming an efficacy of 65% of AZA, it was calculated that 80 participants
were needed to be enrolled in the trial to detect differences in significant endoscopic
recurrence among the groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The random allocation sequence
was delivered by a randomisation program
written in Visual Basic version 6”
Comment: Computer generated randomi-
sation
Allocation concealment (selection bias) Unclear risk Quote: “Randomization took place in the
pharmacy of the Leuven University Hospi-
tals within 2 weeks after surgery”
Comment: insufficient information to
make judgment
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo identical to active drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “At week 12 and 52, an ileo-
colonoscopy was performed with determi-
nation of Rutgeerts’ score for ileal recur-
rence of CD by an endoscopist who was
unaware of treatment assignment”
Comment: Probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Both intention-to treat and per-
protocol analyses were performed”
Comment: ITT analysis applied and attri-
tion rates were similarly low across groups
Selective reporting (reporting bias) Low risk Trial registration not available, however, all
outcomes stated in the method section ad-
equately reported
Other bias Low risk Quote: “The characteristics of the study
populations in the AZA and placebo group
were comparable’”
Comment: Groups well balanced at base-
line, no other apparent sources of bias de-
tected
Hanauer 2004
Methods Study design: RCT, multicentre
Setting: USA and Belgium / 5 centres; 1992 to 1996
Participants Inclusion: Participants18 to 65 years of age, with diagnosis of CD for at least 6 months
and scheduled for curative ileo-caecal resection; ability to start oral nutrition within 7
days of operation, need for curative ileo-caecal resection, and resection margins free of
inflammation
Exclusion: Active perianal disease or any active disease in other segments of the intestine,
anti-TNF-α, and/or investigational treatment within 4 months prior to surgery; current
treatment with 5-ASA, azathioprine/6MP, or methotrexate; bowel surgery performed
less than 3 months previously; history of colostomy or ileostomy; infections, neoplasia,
or uncontrolled diseases; or anticipation of noncompliance with protocols. Subjects who
were receiving steroids preoperatively were tapered and weaned according to a strict
schedule
Age (IG1 / IG2) mean (SD): 34.4 ±11.0 years overall; 34.9 ±11.5 years versus 34.1
±10.9 years versus 34.2 ±10.9 years
Sex (M:F): 60:71 overall; (23:24) versus (19:25) versus (18:22)
Type of surgery: Not reported
Previous surgery (IG1+IG2): 18 (7/11)
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Start of intervention after surgery: Therapy initiated before postoperative hospital
discharge
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): Not reported
Number randomised (N = 131): 47/44/40
Number analysed (N = 131): (47/131) versus (44/131) versus (40/131)
Post-randomisation exclusion (n = 27): (12/47) versus (7/44) versus (8/40) (Withdrew
consent-5 (1/2/2); Surgical complication-3 (2/0/1); Noncompliance-9 (2/4/3); Lost to
follow-up-10 (4/2/4)
Interventions Group 1: 50 mg of 6-mercaptopurine (Purinethol) once daily
Group 2: 3 g of Mesalamine (Pentasa); 4 capsules of 250 mg, 3 times daily
Group 3: Identical matching placebo
All participants: Presurgical therapy, including aminosalicylates, antibiotics, or im-
munomodulators, was discontinued before surgical resection and was not allowed during
the postoperative trial. Preoperative treatment with corticosteroids was completely ta-
pered by 3 months after hospital discharge at a rate determined by the treating physician.
No concurrent treatment for Crohn’s disease, aside from topical therapy for perianal
disease, was allowed during the duration of the trial. Continuous use of nonsteroidal
anti-inflammatory drugs was not allowed during the study. If the white blood cell count
and platelet counts fell below 4500/L or 150,000/L, respectively, the dosage of 6-MP
was reduced by one half
Outcomes Duration of study: 24 months
1. Endoscopic recurrence defined as i≥1 according to the Rutgeerts scoring system: i1-
i2 mild to moderate; i3-i4 severe. Relapse defined as i≥1
2. Clinical recurrence defined as CDAI > 150 points or an increase in CDAI score of
> 70 points or higher from baseline
3. Histological score assessed by the Geboes scoring system
4.Adverse events
5.Serious adverse events
6.Withdrawal due to adverse events
Notes Funding source: Not reported; However, authors contacted by email on 02/08/2018
and declared none
Conflict of interest: Not reported; However, authors contacted by email on 02/08/2018
stating that study was funded by Crohn’s and Colitis Foundation
Power calculation: Sample size calculations were performed for the endoscopic criteria,
using 2-sided of 0.05 and 80% power, based on a predicted endoscopic recurrence of
75% at 1 year in the placebo group. A sample size of 50 in each group allows sufficient
power to detect a 40% reduction in mild Crohn’s disease lesions and a 75% reduction
in more severe lesions at 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quotes: Patients were randomised by a cen-
tral computer by permuted blocks of 6 (un-
known to investigators) per centre to re-
ceive mesalamine (Pentasa; Marion Mer-
rill Dow, Kansas City, MO) 3 g daily, 6-
MP (Purinethol; Burroughs Wellcome, Re-
search Triangle Park, NC) 50 mg daily, or
placebo
Comment: Computer generated random
sequence
Allocation concealment (selection bias) Low risk Quotes: “Medications were prepared and
dispensed by an assigned pharmacist at each
site’s investigational pharmacy who was not
directly involved in the care of the patients”
Comment: Treatment controlled by phar-
macies at each centre
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotes: “Medications were prepared and
dispensed by an assigned pharmacist at each
site’s investigational pharmacy who was not
directly involved in the care of the patients”
and “An evaluating (treating) physician fol-
lowed up each patient and was blinded as
to the study drug and laboratory results”
Comment: Placebo-controlled, double-
blind RCT. However, it is unclear whether
both study drugs were sufficiently identical
with the placebo to blind study participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotes: “Patient evaluation consisted of as-
sessments of clinical, endoscopic, and ra-
diographic disease activity at each study site
by the blinded physician” and “Colono-
scopic examinations with endoscopic de-
scriptions and photography of the anas-
tomosis and pre-anastomotic ileum were
performed by the blinded investigators
(all gastroenterologists) at months 6, 12,
and 24“ and “Radiographic interpretations
were performed by the blinded inflamma-
tory bowel disease radiologist at each insti-
tution”
Comment:Assessors blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotes: “The clinical recurrence rates were
determined using ITT”
Comment: ITT analysis applied, attrition
low, similar and balanced across groups
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Selective reporting (reporting bias) Low risk Comment: All outcomes stated in the
method section reported
Other bias Low risk Quote: ”There were no statistical differ-
ences in patient age, sex, disease duration,
indications for surgical resection, or preop-
erative disease activity among the 3 groups”
Comment: Groups well balanced at base-
line. No other apparent sources of bias de-
tected
Herfarth 2006
Methods Study design: Multicentre RCT
Setting: Not stated (multicentre RCT)
Participants Inclusion: People with Crohn’s who had undergone resective surgery
Exclusion: Homozygous TPMT
Age: Not reported
Sex: Not reported
Type of surgery: Not reported
Previous surgery: Not reported
Start of intervention after surgery: within 2 weeks postoperative
Medication use (IG1+ IG2):
Smoker (IG1 / IG2): Not reported
Number randomised (N = 79): 42/37
Number analysed (N = 37): 18/19
Post-randomisation exclusion (n = 42)
Interventions Group 1: 2.0 to 2.5 mg/kg body weight/day azathioprine
Group 2: 4 g 5-ASA/day
All participants: Not stated
Outcomes Duration of study: 1 year (study was discontinued after one year)
1. Treatment failure (due to severe endoscopic recurrence, lack of efficacy and AE related
to study drug)
2. Clinical or severe endoscopic relapse
3. Severe endoscopic relapse
4. Clinical relapse (reviewer calculated: clinical or severe endoscopic relapse minus severe
endoscopic relapse)
5. Adverse events
6. Withdrawal due to adverse events
Notes Funding source: Dr. Falk Pharma GmbH, Freiburg, Germany
Conflict of interest: Not reported
Power calculation: Not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients in the present study were assigned
to one of the two treatment groups (5-ASA
or azathioprine) at random
For creation of the randomisation list the
programme ”Rancode +“ (version 3.6) of
IDV, Gauting (Germany) was used. The
randomisation into two treatment groups
was performed in blocks of four. After
voluntary written informed consent was
obtained and basic selection criteria were
checked, the investigator requested the al-
location of a unique patient code number
(randomisation number, consecutively al-
located to each patient), and received med-
ication packs with the randomisation num-
ber for the patient”
Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Allocation concealment (selection bias) Low risk “The randomization code was prepared
and stored by a statistician from a CRO,
who was not involved in the conduct nor in
the analysis of the study. The Qualified Per-
son of the Sponsor and the contract manu-
facturer responsible for the preparation of
the double-dummy patients sets received a
copy of the randomization list, which was
safely stored at both sites, without allowing
access by other people. Neither the investi-
gator nor the study team from the clinical
operation from the sponsor nor the CRO
had access to the random list”
Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “This was a double-blind, double-dummy
study. Patients randomized to administer
5-ASA had to take 5-ASA VERUM tablets
AND azathioprine PLACEBO tablets. Pa-
tients randomized to receive azathioprine
had to administer azathioprine VERUM
tablets AND 5-ASA PLACEBO tablets
Therefore, neither the investigator, nor the
patients, nor the sponsor were ware of the
TX a patient received until the database was
clean, closed, and the code was broken”
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Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “This was a double-blind, double-dummy
study. Patients randomized to administer
5-ASA had to take 5-ASA VERUM tablets
AND azathioprine PLACEBO tablets. Pa-
tients randomized to receive azathioprine
had to administer azathioprine VERUM
tablets AND 5-ASA PLACEBO tablets
Therefore, neither the investigator, nor the
patients, nor the sponsor were ware of the
TX a patient received until the database was
clean, closed, and the code was broken”
Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “The study was stopped prema-
turely after an interim-analysis due to a
high therapy failure rate. 38 patients (AZA
18 patients; 5-ASA 20 patients) completed
the study and could be evaluated regarding
the primary endpoint therapy failure. The
other patient terminated the trial prema-
turely due to the study stop, but were also
evaluated for adverse events (AE) and ad-
verse drug reactions (ADR)”
Comment: 51% of randomised partici-
pants discontinued. High risk for primary
outcome and low risk for AE and with-
drawal due to AE
Selective reporting (reporting bias) Unclear risk Insufficient information as trial registration
was not available and study was published
as abstract
Other bias Unclear risk Insufficient information as study was pub-
lished as abstract
Lopez-Sanroman 2017
Methods Study design: RCT, multicentre
Setting: Spain, 22 centres; 2012 to 2015
Participants Inclusion: Adults (18-70 years) who underwent a resective surgical procedure (radical
or non-radical) for a CD-specific lesion at 1 of the participating centres;
diagnosis of CD established by generally accepted endoscopic, histological, and/or ra-
diological criteria at least 6 months before surgery; evaluation of disease location by a
complete investigation of the gastrointestinal tract (gastroscopy, colonoscopy, and small
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bowel radiography) within a maximum of 1 year before the index surgery; and ability to
start oral nutrition (and, thus, oral medication) within the first 10 postoperative days
Exclusion: Contraindications for use of mesalamine; pregnancy or intention of preg-
nancy within the next 18 months; nursing; short bowel syndrome; clinically significant
lactase deficiency; any severe additional disease; diagnosis of primary sclerosing cholangi-
tis; presence of an ileocolonic stoma; more than 3 surgeries preceding the index surgery;
and failure to obtain informed consent
Age (IG1 / IG2) median [interquartile range]: overall age not reported; 37.00 years
[31.00 to 47.00 years] versus 35.00 years [30.0 to 40.0 years]
Sex (M:F): 42:42 overall; (23:16) versus (19/26)
Type of surgery: not reported
Previous surgery (IG1+IG2): 6 (3/3)
Start of intervention after surgery: after surgery (consent obtained before surgery)
Medication use (IG1+ IG2): Glucocorticoids-80 (38/42); Immunosuppressants [thiop-
urines or methotrexate]-63 (28/35); Anti-TNF-α - 49 (21/28)
Smoker (IG1 / IG2): 20 (9/11)
Number randomised (N = 85): 40/45
Number analysed (N = 84): (39/40) versus (40/40)
Post-randomisation exclusion (n = 3): (1/40) versus (2/45) Consent withdrawal before
treatment-1 (0/1); Loss to follow-up -2 (1/1)
Interventions Group 1: AZA 2.5 mg/kg/day for one year + Metronidazole 250 mg three times a day
by mouth was added for the first 3 months
Group 2: ADA 160 mg subcutaneously, then 80 mg at Week 2, or 40 mg at Week 4
and every 2 weeks thereafter for one year + Metronidazole 250 mg three times a day by
mouth was added for the first 3 months
All participants: Adherence to therapy was assessed by direct questioning and by count-
ing of returned medication
Outcomes Duration of study: 52 weeks
1. Endoscopic recurrence defined as i ≥ 2b, 3 and 4 based on Rutgeerts score (24 and
52 weeks)
2. Clinical recurrence defined by 1 of the following: increase in CDAI above 200 (24
and 52 weeks) (CDAI ≥ 200: derived from number randomised - remissions)
3.Radiologic recurrence rate
4.Health Related Quality of Life
5. Adverse events
6.Serious adverse events
7.Withdrawal due to adverse events
Notes Funding source: unrestricted grant from AbbVie [Spanish Working Group on Crohn’s
Disease and Ulcerative Colitis] The funding group had no role in the study design,
data collection, data analysis, data interpretation, writing of the report, or decisions
concerning publication. The authors had unrestricted access to the data; the decision to
submit the paper for publication was solely and entirely to theirs
Conflict of interest: All authors have declared conflict of interest (mainly grants, personal
fees, collaboration with AbbVie outside the submitted work, research funding from
AbbVie etc.)
Power calculation: The difference in the proportion of endoscopic recurrence between
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treatment groups was estimated at 35% (10% for ADA + metronidazole and 45% for
AZA + metronidazole), considering a type 1 error of 5%, a two-tailed contrast with
Yates’ continuity correction, 90% power (1-type II error), and an allocation ratio of 1:
1. Therefore, 38 participants per treatment group would be needed. Withdrawals were
estimated at 10%. The minimal sample was estimat3d at 84 evaluable participants.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote:“Central randomisation was based
on a pre-generated block randomisation list
stratified by centre.” and “Patients were as-
signed [1:1] to..”
Comment:Central randomisation
Allocation concealment (selection bias) Low risk Quote:“Central randomisation was based
on a pre-generated block randomisation list
stratified by centre...Allocation was con-
cealed by means of a computer-generated
randomisation schedule without stratifica-
tion or block allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote:“Neither patients nor investigators
were blinded to the administered treat-
ment”
Comment: No blinding of personnel and
participants performed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote:“A video recording of the last 15 cm
of the neo-terminal ileum was evaluated by
an endoscopist blinded to treatment alloca-
tion and experienced in application of the
Rutgeerts score [VP]” and “..MRE, which
was evaluated centrally by an experienced
blinded reader [JR];”
Comment:Outcome assessors we blinded
to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote:“We defined the following popula-
tions: 1] the intention-to-treat [ITT] pop-
ulation, which included all consenting pa-
tients who were randomised and received
at least one dose of the study medications”
Comment: ITT analysis applied, reasons
for withdrawal reported and attrition rates
were balanced across groups
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Selective reporting (reporting bias) High risk Trial regis-
tration was available (NCT01564823) and
all prespecified outcomes were reported in
the study except health related quality of
life which was only reported as a P-value in
an abstract
Other bias Low risk Quote:“The groups were similar regarding
baseline characteristics, including smok-
ing status, previous resections, CD pheno-
type, previous perianal disease, and previ-
ous drug exposure”
Comment: Groups well balanced at base-
line. No other apparent sources of bias de-
tected
Mowat 2016
Methods Study design: RCT, multicentre,
Setting: UK / 29 secondary and tertiary hospital; 2008 to 2012
Participants Inclusion:Participants aged at least 16 years (Scotland) or 18 years (England and Wales)
who had a diagnosis of Crohn’s disease and an ileocolic or small bowel resection within
the preceding 3 months were eligible for inclusion. Patients successfully treated for a
malignancy and in remission for at least 5 years were also eligible
Exclusion: Residual active Crohn’s disease present after surgery, known intolerance or
hypersensitivity to thiopurines, known need for further surgery, stricturoplasty alone,
formation of a stoma, active or untreated malignancy, absent thiopurine methyltrans-
ferase activity, substantial abnormalities of liver function tests or full blood count, and
pregnancy. Patients receiving treatment for active Crohn’s disease at random allocation
Age (IG1 / IG2) mean (SD): 38.76 ± 13.1 years overall; 39.2 ± 12.08 years versus 38.
21 ± 13.4 years
Type of surgery: not reported
Previous surgery (IG1+IG2): not reported
Start of intervention after surgery: ≤ 3 months
Medication use (IG1+ IG2): not reported
Smoker (IG1 / IG2): not reported
Number randomised (N = 240): 128/112
Number analysed (N = 240): (128/128) versus (112/112)
Post-randomisation exclusion (n = 56): abnormal blood test results-18 (12/6); early
withdrawal - 21 (8/13); loss to follow-up - 16 (8/7); death-1 (0/1)
Interventions Group 1: Once daily oral 6-mercaptopurine, at a dose of 1 mg/kg bodyweight rounded to
the nearest 25 mg. Patients with low thiopurine methyltransferase activity were prescribed
half the normal dose for 3 years
Group 2: Identical matched placebo for 3 years
All participants: Blood monitoring was done weekly for the first 6 weeks and thereafter
at 6-weekly intervals. Patients with abnormal results had a dose reduction, temporary
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cessation, or cessation as per a study algorithm. At each study visit, the following data
were collected: CDAI, physical examination, concomitant medications, and patient-
reported outcomes, including the IBDQ
Outcomes Duration of study: 3 years
1. Clinical recurrence defined as CDAI score of over 150 and a 100-point increase
from baseline, and the need for anti-inflammatory rescue treatment or primary surgical
intervention
2. Secondary endpoint of clinical recurrence defined as reaching either of the individual
components of the primary outcome (i.e. either a CDAI score of >150 and a 100-point
increase from baseline, or the need for anti-inflammatory rescue treatment or primary
surgical intervention)
3. Endoscopic relapse defined as a Rutgeerts score of ≥ i2
4. Crohn’s Disease Endoscopic Index of Severity
5. Health-related quality of life
6. Adverse events
7. Severe adverse events
8.Withdrawal due to adverse events
Notes Funding source: Funded by the Efficacy and Mechanism Evaluation programme, a
Medical Research Council and National Institute for Health Research (NIHR) partner-
ship. They had no role in study design, data collection, data analysis, data interpretation,
or writing of the report
Conflict of interest: Authors declare none conflicting interests
Power calculation: A sample size of 234 patients was needed to give 80% power to
detect a reduction in the frequency of recurrence from 50% in the placebo group to 30%
in the treatment group by 3 years at the 5% level of significance
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were randomly assigned
(1:1) to mercaptopurine or identical
matched placebo using a computer-gen-
erated web-based randomisation system
managed by the Edinburgh Clinical Trials
Unit (University of Edinburgh, Edinburgh,
UK)
Comment:computer-generated web-based
random sequence
Allocation concealment (selection bias) Low risk Quote: “Patients’ details were entered into
the randomisation system before random
allocation and were concealed at randomi-
sation”
Comment: Web-based central allocation
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients and their carers and physi-
cians were masked to the treatment alloca-
tion”
Comment: The study is placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Blood monitoring results were re-
viewed by an independent central clini-
cian masked to treatment allocation and to
mean corpuscular volume results. To pro-
tect masking, investigators were informed
that sham dose reductions were planned
for patients on placebo. However, on the
advice of the data monitoring committee,
sham dose reductions did not occur; the in-
vestigators were not informed of this”
Comment: Outcome assessors were
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Analyses were by intention to
treat”
Comment: ITT analysis applied. Overall
attrition rate of 23% when compared with
the event risk (30%), was not considered
sufficient to lead to bias
Selective reporting (reporting bias) Low risk Trial registration available (IS-
RCTN89489788) and all outcomes stated
in the method section reported
Other bias Low risk Quote: “Baseline characteristics were simi-
lar between study groups”
Comment: Groups well balanced at base-
line. No other apparent sources of bias de-
tected
Reinisch 2010
Methods Study design: RCT, multicentre
Setting: Austria, the Czech Republic, Germany and Israel ; 21 centres, 2002 to 2007
Participants Inclusion: Male or female patients aged 18-70 years with a diagnosis of CD confirmed by
endoscopy and histology were eligible for screening if they had (1) undergone resection of
the terminal ileum and partial colectomy with ileocolonic resection for complications of
ileal CD with construction of an ileocolonic anastomosis in the preceding 6-24 months;
(2) not experienced clinical recurrence due to CD since resection; and (3) a Crohn’s
disease activity index (CDAI) score <200 in the preceding 1-2 weeks. Patients with
moderate endoscopic recurrence (Rutgeerts grade i2a: >5 aphthous lesions with normal
mucosa between the lesions, or skip areas of larger lesions) or severe endoscopic recurrence
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(i3-i4: diffuse aphthous ileitis with diffusely inflamed mucosa, or diffuse inflammation
with larger ulcers, nodules and/or narrowing) were recruited into the study
Exclusion: Patients with a short bowel syndrome, an ileocolonic stoma, a thiopurine
methyltransferase genotype, patients who had received treatment with immunosuppres-
sant agents (methotrexate, ciclosporin, 6-MP, azathioprine or 6-thioguanine (6-TG) or
anti-tumour necrosis factor a (TFNa) since resection, corticosteroids or oral antibiotics
(e.g. metronidazole or ciprofloxacin) for >4 weeks since resection, non-steroidal anti-
inflammatory drugs (NSAIDs) within the preceding 2 weeks (other than paracetamol
or low-dose acetylsalicylic acid); patients who currently had stricturoplasty (unless the
present stricture plasty macroscopically showed no inflammation at the time of the index
operation) or had serum creatinine >130 µmol/l. Patients were excluded if endoscopy
revealed no lesions (grade i0), <5 aphthous lesions (grade i1) and/or if lesions were con-
fined to the ileocolonic anastomosis (i.e. <1 cm long) (grade i2b). Patients in the latter
category (grade i2b) were excluded since this presentation is associated with a lower risk
of clinical recurrence
Age (IG1 / IG2) mean: 35.8 ± 12.08 years overall; 35.5 ± 13.6 years versus 36.0 ± 10.
7 years
Sex (M:F): 44: 34 overall; (24:17) versus (20/17)
Type of surgery: not reported
Previous surgery (IG1+IG2): 1 or 2 surgeries-114 (63/51)); >2 surgeries -12 (4/8)
Start of intervention after surgery: 6 to 24 months
Medication use (IG1+ IG2): Mesalazine - 54 (28/26); Sulfasalazine- 5 (4/1); Budes-
onide- 22 (9/13); Corticosteroids- 39 (23/16); Azathioprine- 14 (6/8); Infliximab-3 (2/
1); Other - 12 (6/6)
Smoker (IG1 / IG2): 37 (17/20)
Number randomised (N = 78): 41/37
Number analysed (N = 78): (41/41) versus (37/37)
Post-randomisation exclusion (n = 9): (4/41) versus (5/37) ; Lack of cooperation-7 (4/
3); lack of efficacy-2 (0/2)
Interventions Group 1: Azathioprine 2.0 - 2.5 mg/kg/day (Azafalk 50 mg tablets) + placebo mesalazine
tablets
Group 2: Mesalazine 4 g/ day (Eudragit L-coated 500 mg tablets (Salofalk)) + placebo
azathioprine tablets
All participants: Medications prohibited during the study: immunosuppressants other
than study drug, allopurinol, oxipurinol or thiopurinol, azathioprine-containing or
mesalazine containing drugs other than study drug, anti-TNF-α therapy, oral antibiotics
for >4 weeks or more than three cycles of 2 weeks, NSAIDs for >2 weeks, corticosteroids
and cimetidine
Outcomes Duration of study: 52 weeks
1. Therapeutic failure (Clinical relapse) defined as CDAI score ≥ 200 and an increase
of ≥ 60 points from baseline or study drug discontinuation due to lack of efficacy or an
intolerable adverse drug reaction
2. Endoscopic recurrence defined by endoscopic Rutgeerts score ≥ i2 only
3. Health-related quality of life based on IBDQ score at 12 months
4. Adverse events
5.Clinical recurrence follow-up defined as a Rutgeerts score between i2-i4 within 24
months after the 1-year treatment
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Reinisch 2010 (Continued)
Notes Funding source: Dr Falk Pharma GmbH, Freiburg, Germany
Conflict of interest: WR has received an unrestricted grant from Dr. Falk Pharma. EFS
and KRH have received speaker’s honoraria. KD, RG and RM are employees of Dr.
Falk Pharma. SA, WP, OS, ML, SB-M, AT, ES and MS have no conflicts of interest
to declare. In part, AT, ES and MS are supported by the Robert Bosch Foundation,
Stuttgart, Germany
Power calculation: The sample size calculation for the primary end point estimated that
62 evaluable patients (31 per treatment arm) were needed to have 80% power to detect
a difference of 35% in favour of azathioprine versus mesalazine for the reduction in the
1 year therapeutic failure rate (one-sided α=0.025). To allow for non-evaluable patients,
a population size of 76 patients (38 per treatment arm) was planned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “..a central randomisation was per-
formed via five computer-generated ran-
domisation lists (using the program ‘Ran-
code +’ (version 3.6) of IDV, Gauting, Ger-
many), which were generated for the five
body weight classes (40-50 kg, 51-60 kg,
61-75 kg, 76-100 kg and 101-128 kg),
each in blocks of four, with medication dis-
tributed to each centre according to this
list”
Comment: Computer-generated randomi-
sation
Allocation concealment (selection bias) Low risk Centralized randomisation in blocks of 4
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “To maintain investigator and pa-
tient blinding, patients randomised to
azathioprine received verum azathioprine
tablets and placebo mesalazine tablets;
those randomised to mesalazine received
verum mesalazine tablets and placebo aza-
thioprine tablets”
Comment: a double-blind, double-
dummy RCT
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to make judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The intention-to-treat (ITT) pop-
ulation was defined as all randomised pa-
tients who received 1 dose of study medi-
cation”
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Reinisch 2010 (Continued)
Comment:The intention-to-treat (ITT)
population was defined as all randomised
patients who received 1 dose of study med-
ication
Selective reporting (reporting bias) Low risk Trial registration avail-
able (NCT00946946) and all prespecified
outcomes were reported
Other bias Low risk Quote: “Baseline characteristics were simi-
lar between treatment groups apart from a
lower mean CDAI value in the azathioprine
cohort (70 versus 102 in the mesalazine
arm) and a higher proportion of azathio-
prine patients with a penetrating disease be-
haviour (66% versus 43%)”
Comment: Some differences at baseline;
study supported by Falk Pharma but con-
flict of interest declared. No other apparent
sources of bias detected
Savarino 2013
Methods Study design: RCT, single
Setting: Italy; University Hospital of Genoa; 2008 to 2010
Participants Inclusion: Adult patients with ileal or ileocolonic CD within 4 weeks of resection of
macroscopically diseased bowel with anastomosis between normal ileum and colon
Exclusion: Patients with (i) more than 10 years of CD requiring first resective surgery
for short (10 cm) fibrostenotic stricture, (ii) macroscopically active disease not resected
at the time of surgery, and (iii) presence of a stoma
Age (IG1 / IG2) median (range): not reported, overall > 18 years; 45 (22 to 66 years)
versus 46 (25 to 65 years)
Sex (M:F): 25:26 overall; (8:8) versus (9:8) versus (8:10)
Type of surgery: not reported
Previous surgery (IG1+IG2): one-40 (12/15/13); two-9 (3/2/4); three-2 (1/0/1)
Start of intervention after surgery: 2 to 4 weeks
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): 19 (9/4/6)
Number randomised (N = 51): 16/17/18
Number analysed (N = 51): (16) versus (17) versus (18)
Post-randomisation exclusion (n = 5): (1/16 ) versus (2/17) versus (2/18) (unclear)
Interventions Group 1: Adalimumab subcutaneous injections 160 / 80 mg at 0 and 2 weeks, followed
by 40 mg every 2 weeks for 2 years
Group 2: Azathioprine (Azafor, Sofar S.P.A., Milan, Italy), at the dose of 2 mg / kg every
day for 2 years
Group 3: Mesalamine (Pentasa, Ferring S.P.A., Milan, Italy), at the dose of 3 g / day
divided in 3 doses for 2 years
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Savarino 2013 (Continued)
All participants: Patients on antibiotics or immunomodulators at entry into the study
discontinued these medications 12 weeks before surgery. Continuous use of nonsteroidal
anti-inflammatory drugs was not allowed during the study. No other medications were
prescribed except for occasional tablets of paracetamol or tramadol. Patients were sub-
jected to endoscopy at 12 and 24 months; small bowel enteroclysis or magnetic resonance
imaging at 12 and 24 months; physical examination with interviews, together with an
extensive battery of blood tests weekly for the first 4 weeks and then every 2 months,
and completed an IBD-Q at 1 month before surgery and at 12 and 24 months aft er
surgery. The CDAI was determined at each study visit. In addition, adverse events were
ascertained at each visit
Outcomes Duration of study: 2 years
1. Clinical recurrence d defined as a score of ≥ 2 on the clinical recurrence grading
scale 1-4 proposed by Hanauer et al
2. Clinical recurrence based on CD activity index (CDAI) was calculated for each
patient and recurrence was set in case of a score > 200, whereas clinical remission was
defined by a CDAI score of < 150
2. Endoscopic recurrence defined by a Rutgeerts score of ≥ i2
3. Radiologic recurrence defined as a score of ≥ 2 on the radiographic recurrence
grading scale (where 1 indicates normal; 2, mucosal edema / aphthoid ulcers; 3, linear
ulcers / cobblestoning; and 4, strictures / fistulas / inflammatory mass)
4. Health-related quality of life
5. Median Lémann Index
5. Adverse events
Notes Funding source: supported by research funds of the university
Conflict of interest: Authors declare no conflict of interest
Power calculation: we considered reasonable to hypothesize an endoscopic recurrence
rate of ~ 80 % and 15 % and a clinical recurrence rate of ~ 65 % and 5 % for the
mesalamine and ADA groups, respectively, at 2 years of follow-up. This estimation has
been supported by the results shown in previous trials on postoperative CD relapse.
Thus, based on these data, 13 patients per treatment group resulted to be sufficient to
detect a difference of at least 65 % for endoscopic recurrence and 60 % for clinical
recurrence in favour of the ADA group with a power of 80 % (global type I error of 5
% ). Th e number of patients in each group was increased to 16 to compensate for an
anticipated dropout rate of 15 %
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible and consenting patients
were assigned randomly using a computer-
generated sequence (www. randomizer.org)
to a regimen of…”
Comment: Computer generated random
sequence
54Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Savarino 2013 (Continued)
Allocation concealment (selection bias) Low risk Quote: ”Patient allocation was concealed
and performed by an independent nurse
not involved with the trial“
Comment: Probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study is open-label design
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”“A blinded investigator (P.D.) re-
viewed each patient’s video-recorded pro-
cedure and provided a separate endoscopic
score” and “At the conclusion of the study,
the principal investigator (E.S.) rescored
each patient by re-reviewing the video
recordings in a random and blinded man-
ner”
Comment: Assessors were blinded for en-
doscopic assessments only. However, no in-
formation on clinical assessment of relapse
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Statistical analysis was conducted
according to the intention-to-treat prin-
ciple.” Comment: ITT analysis applied.
Withdrawals and reasons reported
Selective reporting (reporting bias) Low risk Trial registration not available, however, all
outcomes stated in the method section re-
ported
Other bias Low risk Quote: “Characteristics were similar for
sex, age, smoking, duration of CD, disease
behavior, disease location, prior medication
exposure, including IFX, and prior surgical
resection”
Comment: Groups well balanced at base-
line; no other apparent sources of bias de-
tected
Scapa 2015
Methods Study design: RCT; abstract
Setting: Tel Aviv, Israel; study period not reported
Participants Inclusion: All CD patients undergoing a first ileocecectomy for inflammatory compli-
cations were prospectively recruited to the Post OPerative Adalimumab Recurrence Trial
(POPART)
Exclusion: Not reported
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Scapa 2015 (Continued)
Age (IG1 / IG2) median (SD): overall not reported; 30.5 ± 2.3 years versus 34.4 ± 2.5
years
Sex (M:F): not reported
Type of surgery: not reported
Previous surgery (IG1+IG2): not reported
Start of intervention after surgery: < 45 days
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): 4 (1/3)
Number randomised (N = 19)
Number analysed (N = 19): (8) versus (11)
Post-randomisation exclusion (n = ?)
Interventions Group 1: Thiopurine (6-mercaptopurine 1.5 mg/kg/day)
Group 2: Adalimumab 160 mg/ 80 mg and then 40 mg every other week
All participants: All patients underwent ileocolonoscopy at 6 and 12 months to asses
for endoscopic recurrence as defined by the Rutgeert’s score
Outcomes Duration of study: 12 months
1. Endoscopic recurrence defined as a Rutgeert’s score of i0-i1, while advanced lesions
were defined as i2 to i4
Notes Funding source: not reported
Conflict of interest: not reported
Power calculation: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to make judgment
Allocation concealment (selection bias) Unclear risk Insufficient information to make judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to make judgment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to make judgment
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Nineteen patients have reached
the 24-week time point”
Comment: Abstract does not report how
many were randomised, the number of
withdrawals, no information regarding any
adverse event. Authors informed us via
correspondence (12/10/2018) that the full
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Scapa 2015 (Continued)
trial will be published by end of 2018, but
refused to share trial data
Selective reporting (reporting bias) High risk Trial registration avail-
able (NCT01629628), however clinical re-
lapse and adverse events were not reported
in the Abstract. Authors informed us via
correspondence (12/10/2018) that the full
trial will be published by end of 2018, but
refused to share trial data
Other bias Unclear risk Insufficient information to make judgment
RCT: randomised controlled trial; CD: Crohn’s disease; CDAI: Crohn’s disease activity index; IG: intervention group; SD: standard
deviation; M: male; F: Female; TNF: tumour necrosis factor; AZA: azathioprine; ITT; intention-to-treat; mg: milligram; kg: kilogram;
g: gram; WBC: white blood cell count; µu/ml: micro units per millilitre; INF: infliximab; 5-ASA: 5-aminosalicylic acid; 6-MP: 6-
mercaptopurine; L: litre; ADA: adalimumab; NSAID; non-steroidal anti-inflammatory drugs; IBDQ: inflammatory bowel disease
questionnaire; cm: centimetre
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ferrante 2015 Wrong intervention: all patients received azathioprine
Study compared systematic azathioprine therapy to endoscopically driven azathioprine therapy
Mañosa 2013 Wrong intervention: All patients received azathioprine
Study compared combination of azathioprine and metronidazole to azathioprine
NCT01876264 Wrong intervention, extended versus conventional resection
NCT02247258 Trial terminated due to slow recruitment
Nos 2000 Not RCT, confirmed after contacting author
Reinisch 2013 Non randomised follow-up of included study Reinisch 2010
Robb 2015 Not RCT; letter
Vidigal 2014 Wrong population: not post-surgical patients
Wright 2014 Wrong intervention, colonoscopy versus no colonoscopy
Wright 2015 Wrong intervention, colonoscopy versus no colonoscopy
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Zhu 2015 Wrong intervention; herbal supplement
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT03185611
Trial name or title Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn’s
Disease
Methods RCT, parallel design, multi-centre study, single blinded (Outcomes Assessor); Location: China
Participants 120 participants, aged 18 to 65 years
Inclusion criteria:
1. Consecutive patients with Crohn’s disease undergoing intestinal resection of all macroscopic diseased
bowel, with an endoscopically accessible ileocolic anastomosis;
2. Enrolled patients must have one or more risk factor for the development of postoperative recurrence
including penetrating disease behaviour, prior bowel resection, and active smoking.
Exclusion criteria:
1. Severe co-morbidities;
2. With a stoma;
3. With malignancy;
4. Pregnancy;
5. Intolerant of thiopurine drugs;
6. With contraindication of using rifaximin or thiopurine drug
Interventions Two arms; Arm 1: Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/
day) for 3 months after surgery, and then Azathioprine monotherapy (2.0 to 2.5 mg/kg/day) for the next 3
months and Arm 2: Prescribed Azathioprine (2.0 to 2.5 mg/kg/day) for 6 months after surgery
Outcomes Primary: Incidence of endoscopic recurrence 6 months after surgery
Secondary: Adverse effect
Starting date June 14, 2017
Contact information Xiang Gao, MD, PhD; gaoxiangmed@163.com
Notes
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NL1344
Trial name or title Azathioprine maintenance treatment versus infliximab maintenance treatment in Crohn’s disease patients in
remission (Azorix trial)
Methods
Participants Inclusion criteria:
1. Age between 18 and 80 years
2. For at least 6 months a stable dose of combination therapy with IFX and AZA or with IFX and 6MP
3. CD in remission for at least 6 months
Exclusion criteria:
1. Failed attempt to quit medication during combination therapy before
2. Abdominal abscesses, fistulas and fluid collections
3. Comorbidity or extra-intestinal complications that require infliximab treatment
4. Crohn’s disease activity of the upper gastrointestinal tract that requires infliximab treatment
5. Legally incompetent patients
Interventions Two arms. Arm 1:Infliximab consisting of infusions of 5 mg/kg. Patients will receive maintenance therapy at
intervals of 6 to 12 weeks
Arm 2: Azathioprine in a dose of 2.5 mg/kg daily; 6-MP will be continued in a dose of 1.5 mg/kg daily
Outcomes Primary outcome: The occurrence of relapse - defined as a disease activity with a CDAI score greater than
150 - during the 12 months follow-up period
Secondary outcome:Mucosal healing at 12 months; Number of treatment failures after 12 months; Time to
relapse; HRQOL at 12 months, measured by IBDQ
Starting date 1st August 2008
Contact information Dr. P.C.F. Stokkers; p.stokkers@amc.nl
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Azathioprine or 6-mercaptopurine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 12 to 36
months (subgroup by drug
type)
3 408 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.67, 0.92]
1.1 Azathioprine 1 81 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.33, 1.08]
1.2 6-mercaptopurine 2 327 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.68, 0.94]
2 Clinical relapse (subgroup by
length of follow-up)
3 408 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.67, 0.92]
2.1 12 months or less 1 81 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.33, 1.08]
2.2 Over 12 months 2 327 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.68, 0.94]
3 Endoscopic relapse at 12 to 36
months (subgroup by drug
type)
2 321 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.64, 1.13]
3.1 Azathioprine 1 81 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.51, 0.97]
3.2 6-mercaptopurine 1 240 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.81, 1.11]
4 Endoscopic relapse (subgroup by
length of follow-up)
2 321 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.64, 1.13]
4.1 12 months or less 1 81 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.51, 0.97]
4.2 Over 12 months 1 240 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.81, 1.11]
5 Adverse events at 12 to 24
months (subgroup by drug
type)
2 168 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.57, 3.27]
5.1 Azathioprine 1 81 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.18, 3.22]
5.2 6-mercaptopurine 1 87 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.64, 5.75]
6 Adverse events (subgroup by
length of follow-up)
2 168 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.57, 3.27]
6.1 12 months or less 1 81 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.18, 3.22]
6.2 Over 12 months 1 87 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.64, 5.75]
7 Serious adverse events at 24 to
36 months
2 327 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.39, 8.18]
8 Withdrawal due to adverse
events at 12 to 36 months
(subgroup by drug type)
3 408 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.63, 1.29]
8.1 Azathioprine 1 81 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.18, 3.22]
8.2 6-mercaptopurine 2 327 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.50, 2.27]
9 Withdrawal due to adverse
events (subgroup by length of
follow-up)
3 408 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.63, 1.29]
9.1 12 months or less 1 81 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.18, 3.22]
9.2 Over 12 months 2 327 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.50, 2.27]
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Comparison 2. Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 12 to 24
months (subgroup by drug
type)
4 347 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.89, 1.24]
1.1 Azathioprine 3 256 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.94, 1.37]
1.2 6-mercaptopurine 1 91 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.70, 1.18]
2 Clinical relapse (subgroup by
length of follow-up)
4 347 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.89, 1.24]
2.1 12 months or less 1 79 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.84, 1.39]
2.2 Over 12 months 3 268 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.82, 1.39]
3 Endoscopic relapse at 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Radiologic relapse at 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Surgical relapse at 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Adverse events at 12 to 24
months (subgroup by drug
type)
4 346 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.74, 1.07]
6.1 Azathioprine 3 255 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.70, 1.09]
6.2 6-mercaptopurine 1 91 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.54, 3.62]
7 Adverse events (subgroup by
length of follow-up)
4 346 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.74, 1.07]
7.1 12 months or less 1 78 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.70, 1.03]
7.2 Over 12 months 3 268 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.64, 1.38]
8 Serious adverse events at 12 to
24 months (subgroup by drug
type)
3 311 Risk Ratio (M-H, Random, 95% CI) 3.39 [1.26, 9.13]
8.1 Azathioprine 2 220 Risk Ratio (M-H, Random, 95% CI) 4.68 [0.64, 34.12]
8.2 6-mercaptopurine 1 91 Risk Ratio (M-H, Random, 95% CI) 4.69 [0.23, 95.00]
9 Serious adverse events (subgroup
by length of follow-up)
3 311 Risk Ratio (M-H, Random, 95% CI) 3.39 [1.26, 9.13]
9.1 12 months or less 1 78 Risk Ratio (M-H, Random, 95% CI) 19.00 [1.15, 313.35]
9.2 Over 12 months 2 233 Risk Ratio (M-H, Random, 95% CI) 2.63 [1.12, 6.16]
10 Withdrawal due to adverse
events at 12 to 24 months
(subgroup by drug type)
5 425 Risk Ratio (M-H, Random, 95% CI) 2.21 [1.28, 3.81]
10.1 Azathioprine 4 334 Risk Ratio (M-H, Random, 95% CI) 2.76 [1.41, 5.40]
10.2 6-mercaptopurine 1 91 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.54, 3.62]
11 Withdrawal due to adverse
events (subgroup by length of
follow-up)
5 425 Risk Ratio (M-H, Random, 95% CI) 2.21 [1.28, 3.81]
11.1 12 months or less 2 157 Risk Ratio (M-H, Random, 95% CI) 3.54 [0.83, 15.08]
11.2 Over 12 months 3 268 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.03, 3.68]
12 HRQoL - IBDQ > 170 at 24
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
13 HRQoL - IBDQ at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 3. Azathioprine or 6-mercaptopurine versus anti TNF-α
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 12 to 24
months
3 139 Risk Ratio (M-H, Random, 95% CI) 2.89 [1.50, 5.57]
2 Clinical relapse (subgroup by
length of follow-up)
3 139 Risk Ratio (M-H, Random, 95% CI) 2.89 [1.50, 5.57]
2.1 12 months or less 2 106 Risk Ratio (M-H, Random, 95% CI) 2.27 [1.07, 4.82]
2.2 Over 12 months 1 33 Risk Ratio (M-H, Random, 95% CI) 6.12 [1.63, 22.97]
3 Endoscopic relapse at 12 to 24
months (subgroup by drug
type)
4 157 Risk Ratio (M-H, Random, 95% CI) 3.67 [1.05, 12.81]
3.1 Azathioprine 3 138 Risk Ratio (M-H, Random, 95% CI) 3.47 [0.75, 16.03]
3.2 6-mercaptopurine 1 19 Risk Ratio (M-H, Random, 95% CI) 5.5 [0.75, 40.36]
4 Endoscopic relapse (subgroup by
length of follow-up)
4 157 Risk Ratio (M-H, Random, 95% CI) 3.67 [1.05, 12.81]
4.1 12 months or less 3 124 Risk Ratio (M-H, Random, 95% CI) 2.44 [0.83, 7.18]
4.2 Over 12 months 1 33 Risk Ratio (M-H, Random, 95% CI) 10.35 [1.50, 71.32]
5 Radiologic relapse at 12 to 24
months
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Histologic relapse at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Adverse events at 12 to 24
months
2 117 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.83, 1.53]
8 Adverse events (subgroup by
length of follow-up)
2 117 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.83, 1.53]
8.1 12 months or less 1 84 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.65, 1.66]
8.2 Over 12 months 1 33 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.81, 1.78]
9 Serious adverse events at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Withdrawal due to adverse
events at 12 to 24 months
3 139 Risk Ratio (M-H, Random, 95% CI) 3.97 [0.92, 17.22]
11 Withdrawal due to adverse
events (subgroup by length of
follow-up)
3 141 Risk Ratio (M-H, Random, 95% CI) 4.17 [0.99, 17.47]
11.1 12 months or less 2 106 Risk Ratio (M-H, Random, 95% CI) 7.17 [1.32, 38.96]
11.2 Over 12 months 1 35 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.07, 15.62]
12 HRQoL - IBDQ > 170 at 24
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 1 Clinical relapse
at 12 to 36 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 1 Clinical relapse at 12 to 36 months (subgroup by drug type)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
D’Haens 2008 11/40 19/41 6.5 % 0.59 [ 0.33, 1.08 ]
Subtotal (95% CI) 40 41 6.5 % 0.59 [ 0.33, 1.08 ]
Total events: 11 (AZA/6-MP), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
2 6-mercaptopurine
Hanauer 2004 32/47 35/40 45.2 % 0.78 [ 0.62, 0.98 ]
Mowat 2016 66/128 70/112 48.3 % 0.83 [ 0.66, 1.03 ]
Subtotal (95% CI) 175 152 93.5 % 0.80 [ 0.68, 0.94 ]
Total events: 98 (AZA/6-MP), 105 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
Total (95% CI) 215 193 100.0 % 0.79 [ 0.67, 0.92 ]
Total events: 109 (AZA/6-MP), 124 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0021)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
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Analysis 1.2. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 2 Clinical relapse
(subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 2 Clinical relapse (subgroup by length of follow-up)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
D’Haens 2008 11/40 19/41 6.5 % 0.59 [ 0.33, 1.08 ]
Subtotal (95% CI) 40 41 6.5 % 0.59 [ 0.33, 1.08 ]
Total events: 11 (AZA/6-MP), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
2 Over 12 months
Hanauer 2004 32/47 35/40 45.2 % 0.78 [ 0.62, 0.98 ]
Mowat 2016 66/128 70/112 48.3 % 0.83 [ 0.66, 1.03 ]
Subtotal (95% CI) 175 152 93.5 % 0.80 [ 0.68, 0.94 ]
Total events: 98 (AZA/6-MP), 105 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
Total (95% CI) 215 193 100.0 % 0.79 [ 0.67, 0.92 ]
Total events: 109 (AZA/6-MP), 124 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0021)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
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Analysis 1.3. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 3 Endoscopic
relapse at 12 to 36 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 3 Endoscopic relapse at 12 to 36 months (subgroup by drug type)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
D’Haens 2008 22/40 32/41 38.3 % 0.70 [ 0.51, 0.97 ]
Subtotal (95% CI) 40 41 38.3 % 0.70 [ 0.51, 0.97 ]
Total events: 22 (AZA/6-MP), 32 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
2 6-mercaptopurine
Mowat 2016 90/128 83/112 61.7 % 0.95 [ 0.81, 1.11 ]
Subtotal (95% CI) 128 112 61.7 % 0.95 [ 0.81, 1.11 ]
Total events: 90 (AZA/6-MP), 83 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 168 153 100.0 % 0.85 [ 0.64, 1.13 ]
Total events: 112 (AZA/6-MP), 115 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.66, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Chi2 = 2.62, df = 1 (P = 0.11), I2 =62%
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Analysis 1.4. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 4 Endoscopic
relapse (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 4 Endoscopic relapse (subgroup by length of follow-up)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
D’Haens 2008 22/40 32/41 38.3 % 0.70 [ 0.51, 0.97 ]
Subtotal (95% CI) 40 41 38.3 % 0.70 [ 0.51, 0.97 ]
Total events: 22 (AZA/6-MP), 32 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
2 Over 12 months
Mowat 2016 90/128 83/112 61.7 % 0.95 [ 0.81, 1.11 ]
Subtotal (95% CI) 128 112 61.7 % 0.95 [ 0.81, 1.11 ]
Total events: 90 (AZA/6-MP), 83 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 168 153 100.0 % 0.85 [ 0.64, 1.13 ]
Total events: 112 (AZA/6-MP), 115 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.66, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Chi2 = 2.62, df = 1 (P = 0.11), I2 =62%
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Analysis 1.5. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 5 Adverse events
at 12 to 24 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 5 Adverse events at 12 to 24 months (subgroup by drug type)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
D’Haens 2008 3/40 4/41 37.1 % 0.77 [ 0.18, 3.22 ]
Subtotal (95% CI) 40 41 37.1 % 0.77 [ 0.18, 3.22 ]
Total events: 3 (AZA/6-MP), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 6-mercaptopurine
Hanauer 2004 9/47 4/40 62.9 % 1.91 [ 0.64, 5.75 ]
Subtotal (95% CI) 47 40 62.9 % 1.91 [ 0.64, 5.75 ]
Total events: 9 (AZA/6-MP), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 87 81 100.0 % 1.36 [ 0.57, 3.27 ]
Total events: 12 (AZA/6-MP), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
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Analysis 1.6. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 6 Adverse events
(subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 6 Adverse events (subgroup by length of follow-up)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
D’Haens 2008 3/40 4/41 37.1 % 0.77 [ 0.18, 3.22 ]
Subtotal (95% CI) 40 41 37.1 % 0.77 [ 0.18, 3.22 ]
Total events: 3 (AZA/6-MP), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Over 12 months
Hanauer 2004 9/47 4/40 62.9 % 1.91 [ 0.64, 5.75 ]
Subtotal (95% CI) 47 40 62.9 % 1.91 [ 0.64, 5.75 ]
Total events: 9 (AZA/6-MP), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 87 81 100.0 % 1.36 [ 0.57, 3.27 ]
Total events: 12 (AZA/6-MP), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
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Analysis 1.7. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 7 Serious adverse
events at 24 to 36 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 7 Serious adverse events at 24 to 36 months
Study or subgroup 6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanauer 2004 2/47 0/40 25.7 % 4.27 [ 0.21, 86.44 ]
Mowat 2016 3/128 2/112 74.3 % 1.31 [ 0.22, 7.71 ]
Total (95% CI) 175 152 100.0 % 1.78 [ 0.39, 8.18 ]
Total events: 5 (6-MP), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 8 Withdrawal due
to adverse events at 12 to 36 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 8 Withdrawal due to adverse events at 12 to 36 months (subgroup by drug type)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
D’Haens 2008 3/40 4/41 6.2 % 0.77 [ 0.18, 3.22 ]
Subtotal (95% CI) 40 41 6.2 % 0.77 [ 0.18, 3.22 ]
Total events: 3 (AZA/6-MP), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 6-mercaptopurine
Hanauer 2004 9/47 4/40 10.4 % 1.91 [ 0.64, 5.75 ]
Mowat 2016 39/128 41/112 83.3 % 0.83 [ 0.58, 1.19 ]
Subtotal (95% CI) 175 152 93.8 % 1.07 [ 0.50, 2.27 ]
Total events: 48 (AZA/6-MP), 45 (Placebo)
Heterogeneity: Tau2 = 0.18; Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.17 (P = 0.86)
Total (95% CI) 215 193 100.0 % 0.90 [ 0.63, 1.29 ]
Total events: 51 (AZA/6-MP), 49 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 1.9. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 9 Withdrawal due
to adverse events (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 9 Withdrawal due to adverse events (subgroup by length of follow-up)
Study or subgroup AZA/6-MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
D’Haens 2008 3/40 4/41 6.2 % 0.77 [ 0.18, 3.22 ]
Subtotal (95% CI) 40 41 6.2 % 0.77 [ 0.18, 3.22 ]
Total events: 3 (AZA/6-MP), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Over 12 months
Hanauer 2004 9/47 4/40 10.4 % 1.91 [ 0.64, 5.75 ]
Mowat 2016 39/128 41/112 83.3 % 0.83 [ 0.58, 1.19 ]
Subtotal (95% CI) 175 152 93.8 % 1.07 [ 0.50, 2.27 ]
Total events: 48 (AZA/6-MP), 45 (Placebo)
Heterogeneity: Tau2 = 0.18; Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.17 (P = 0.86)
Total (95% CI) 215 193 100.0 % 0.90 [ 0.63, 1.29 ]
Total events: 51 (AZA/6-MP), 49 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 2.1. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 1
Clinical relapse at 12 to 24 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 1 Clinical relapse at 12 to 24 months (subgroup by drug type)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
Ardizzone 2004 35/71 32/71 20.1 % 1.09 [ 0.77, 1.55 ]
Herfarth 2006 33/42 27/37 36.4 % 1.08 [ 0.84, 1.39 ]
Savarino 2013 13/17 9/18 9.0 % 1.53 [ 0.90, 2.60 ]
Subtotal (95% CI) 130 126 65.5 % 1.13 [ 0.94, 1.37 ]
Total events: 81 (AZA/6-MP), 68 (5-ASA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
2 6-mercaptopurine
Hanauer 2004 32/47 33/44 34.5 % 0.91 [ 0.70, 1.18 ]
Subtotal (95% CI) 47 44 34.5 % 0.91 [ 0.70, 1.18 ]
Total events: 32 (AZA/6-MP), 33 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 177 170 100.0 % 1.05 [ 0.89, 1.24 ]
Total events: 113 (AZA/6-MP), 101 (5-ASA)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.26, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 1.80, df = 1 (P = 0.18), I2 =44%
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Analysis 2.2. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 2
Clinical relapse (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 2 Clinical relapse (subgroup by length of follow-up)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Herfarth 2006 33/42 27/37 36.4 % 1.08 [ 0.84, 1.39 ]
Subtotal (95% CI) 42 37 36.4 % 1.08 [ 0.84, 1.39 ]
Total events: 33 (AZA/6-MP), 27 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.57)
2 Over 12 months
Ardizzone 2004 35/71 32/71 20.1 % 1.09 [ 0.77, 1.55 ]
Hanauer 2004 32/47 33/44 34.5 % 0.91 [ 0.70, 1.18 ]
Savarino 2013 13/17 9/18 9.0 % 1.53 [ 0.90, 2.60 ]
Subtotal (95% CI) 135 133 63.6 % 1.07 [ 0.82, 1.39 ]
Total events: 80 (AZA/6-MP), 74 (5-ASA)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.22, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 177 170 100.0 % 1.05 [ 0.89, 1.24 ]
Total events: 113 (AZA/6-MP), 101 (5-ASA)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.26, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 2.3. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 3
Endoscopic relapse at 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 3 Endoscopic relapse at 24 months
Study or subgroup AZA 5-ASA Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 11/17 15/18 0.78 [ 0.52, 1.17 ]
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Analysis 2.4. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 4
Radiologic relapse at 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 4 Radiologic relapse at 24 months
Study or subgroup AZA 5-ASA Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 13/17 15/18 0.92 [ 0.66, 1.28 ]
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Analysis 2.5. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 5
Surgical relapse at 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 5 Surgical relapse at 24 months
Study or subgroup AZA 5-ASA Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardizzone 2004 21/71 26/71 0.81 [ 0.50, 1.29 ]
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Analysis 2.6. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 6
Adverse events at 12 to 24 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 6 Adverse events at 12 to 24 months (subgroup by drug type)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
Ardizzone 2004 18/71 27/71 12.7 % 0.67 [ 0.41, 1.10 ]
Reinisch 2010 32/41 34/37 57.7 % 0.85 [ 0.70, 1.03 ]
Savarino 2013 14/17 14/18 25.8 % 1.06 [ 0.76, 1.47 ]
Subtotal (95% CI) 129 126 96.3 % 0.87 [ 0.70, 1.09 ]
Total events: 64 (AZA/6-MP), 75 (5-ASA)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.05, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.22 (P = 0.22)
2 6-mercaptopurine
Hanauer 2004 9/47 6/44 3.7 % 1.40 [ 0.54, 3.62 ]
Subtotal (95% CI) 47 44 3.7 % 1.40 [ 0.54, 3.62 ]
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(. . . Continued)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 9 (AZA/6-MP), 6 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 176 170 100.0 % 0.89 [ 0.74, 1.07 ]
Total events: 73 (AZA/6-MP), 81 (5-ASA)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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Analysis 2.7. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 7
Adverse events (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 7 Adverse events (subgroup by length of follow-up)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Reinisch 2010 32/41 34/37 57.7 % 0.85 [ 0.70, 1.03 ]
Subtotal (95% CI) 41 37 57.7 % 0.85 [ 0.70, 1.03 ]
Total events: 32 (AZA/6-MP), 34 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
2 Over 12 months
Ardizzone 2004 18/71 27/71 12.7 % 0.67 [ 0.41, 1.10 ]
Hanauer 2004 9/47 6/44 3.7 % 1.40 [ 0.54, 3.62 ]
Savarino 2013 14/17 14/18 25.8 % 1.06 [ 0.76, 1.47 ]
Subtotal (95% CI) 135 133 42.3 % 0.94 [ 0.64, 1.38 ]
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(. . . Continued)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 41 (AZA/6-MP), 47 (5-ASA)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.35, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 176 170 100.0 % 0.89 [ 0.74, 1.07 ]
Total events: 73 (AZA/6-MP), 81 (5-ASA)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.66), I2 =0.0%
0.01 0.1 1 10 100
Favours AZA/6-MP Favours 5-ASA
Analysis 2.8. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 8
Serious adverse events at 12 to 24 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 8 Serious adverse events at 12 to 24 months (subgroup by drug type)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
Ardizzone 2004 15/71 6/71 77.9 % 2.50 [ 1.03, 6.07 ]
Reinisch 2010 10/41 0/37 11.8 % 19.00 [ 1.15, 313.35 ]
Subtotal (95% CI) 112 108 89.7 % 4.68 [ 0.64, 34.12 ]
Total events: 25 (AZA/6-MP), 6 (5-ASA)
Heterogeneity: Tau2 = 1.28; Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 1.52 (P = 0.13)
2 6-mercaptopurine
Hanauer 2004 2/47 0/44 10.3 % 4.69 [ 0.23, 95.00 ]
Subtotal (95% CI) 47 44 10.3 % 4.69 [ 0.23, 95.00 ]
Total events: 2 (AZA/6-MP), 0 (5-ASA)
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
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(. . . Continued)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI) 159 152 100.0 % 3.39 [ 1.26, 9.13 ]
Total events: 27 (AZA/6-MP), 6 (5-ASA)
Heterogeneity: Tau2 = 0.12; Chi2 = 2.20, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
Analysis 2.9. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 9
Serious adverse events (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 9 Serious adverse events (subgroup by length of follow-up)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Reinisch 2010 10/41 0/37 11.8 % 19.00 [ 1.15, 313.35 ]
Subtotal (95% CI) 41 37 11.8 % 19.00 [ 1.15, 313.35 ]
Total events: 10 (AZA/6-MP), 0 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
2 Over 12 months
Ardizzone 2004 15/71 6/71 77.9 % 2.50 [ 1.03, 6.07 ]
Hanauer 2004 2/47 0/44 10.3 % 4.69 [ 0.23, 95.00 ]
Subtotal (95% CI) 118 115 88.2 % 2.63 [ 1.12, 6.16 ]
Total events: 17 (AZA/6-MP), 6 (5-ASA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
0.01 0.1 1 10 100
Favours AZA/6-MP Favours 5-ASA
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(. . . Continued)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 2.23 (P = 0.026)
Total (95% CI) 159 152 100.0 % 3.39 [ 1.26, 9.13 ]
Total events: 27 (AZA/6-MP), 6 (5-ASA)
Heterogeneity: Tau2 = 0.12; Chi2 = 2.20, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 1.75, df = 1 (P = 0.19), I2 =43%
0.01 0.1 1 10 100
Favours AZA/6-MP Favours 5-ASA
Analysis 2.10. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 10
Withdrawal due to adverse events at 12 to 24 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 10 Withdrawal due to adverse events at 12 to 24 months (subgroup by drug type)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
Ardizzone 2004 15/71 6/71 37.9 % 2.50 [ 1.03, 6.07 ]
Herfarth 2006 7/42 3/37 18.3 % 2.06 [ 0.57, 7.38 ]
Reinisch 2010 10/41 1/37 7.4 % 9.02 [ 1.21, 67.15 ]
Savarino 2013 1/17 0/18 3.0 % 3.17 [ 0.14, 72.80 ]
Subtotal (95% CI) 171 163 66.7 % 2.76 [ 1.41, 5.40 ]
Total events: 33 (AZA/6-MP), 10 (5-ASA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.97 (P = 0.0029)
2 6-mercaptopurine
Hanauer 2004 9/47 6/44 33.3 % 1.40 [ 0.54, 3.62 ]
Subtotal (95% CI) 47 44 33.3 % 1.40 [ 0.54, 3.62 ]
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(. . . Continued)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 9 (AZA/6-MP), 6 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 218 207 100.0 % 2.21 [ 1.28, 3.81 ]
Total events: 42 (AZA/6-MP), 16 (5-ASA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.04, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =23%
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
Analysis 2.11. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 11
Withdrawal due to adverse events (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 11 Withdrawal due to adverse events (subgroup by length of follow-up)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Herfarth 2006 7/42 3/37 18.3 % 2.06 [ 0.57, 7.38 ]
Reinisch 2010 10/41 1/37 7.4 % 9.02 [ 1.21, 67.15 ]
Subtotal (95% CI) 83 74 25.7 % 3.54 [ 0.83, 15.08 ]
Total events: 17 (AZA/6-MP), 4 (5-ASA)
Heterogeneity: Tau2 = 0.44; Chi2 = 1.60, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.71 (P = 0.087)
2 Over 12 months
Ardizzone 2004 15/71 6/71 37.9 % 2.50 [ 1.03, 6.07 ]
Hanauer 2004 9/47 6/44 33.3 % 1.40 [ 0.54, 3.62 ]
Savarino 2013 1/17 0/18 3.0 % 3.17 [ 0.14, 72.80 ]
0.01 0.1 1 10 100
Favours AZA/6-MP Favours 5-ASA
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(. . . Continued)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 135 133 74.3 % 1.95 [ 1.03, 3.68 ]
Total events: 25 (AZA/6-MP), 12 (5-ASA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
Total (95% CI) 218 207 100.0 % 2.21 [ 1.28, 3.81 ]
Total events: 42 (AZA/6-MP), 16 (5-ASA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.04, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
Favours AZA/6-MP Favours 5-ASA
Analysis 2.12. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 12
HRQoL - IBDQ > 170 at 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 12 HRQoL - IBDQ > 170 at 24 months
Study or subgroup AZA 5-ASA Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 2/17 3/18 0.71 [ 0.13, 3.72 ]
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Favours AZA Favours 5-ASA
81Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.13. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 13
HRQoL - IBDQ at 12 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 13 HRQoL - IBDQ at 12 months
Study or subgroup AZA 5-ASA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Reinisch 2010 41 9 (17.7) 37 5 (27.4) 4.00 [ -6.36, 14.36 ]
-100 -50 0 50 100
Favours AZA Favours 5-ASA
Analysis 3.1. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 1 Clinical
relapse at 12 to 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 1 Clinical relapse at 12 to 24 months
Study or subgroup AZA anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Armuzzi 2013 2/11 1/11 8.5 % 2.00 [ 0.21, 18.98 ]
Lopez-Sanroman 2017 14/39 7/45 67.0 % 2.31 [ 1.04, 5.13 ]
Savarino 2013 13/17 2/16 24.5 % 6.12 [ 1.63, 22.97 ]
Total (95% CI) 67 72 100.0 % 2.89 [ 1.50, 5.57 ]
Total events: 29 (AZA), 10 (anti TNF- )
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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82Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.2. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 2 Clinical
relapse (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 2 Clinical relapse (subgroup by length of follow-up)
Study or subgroup AZA/6-MP anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Armuzzi 2013 2/11 1/11 8.5 % 2.00 [ 0.21, 18.98 ]
Lopez-Sanroman 2017 14/39 7/45 67.0 % 2.31 [ 1.04, 5.13 ]
Subtotal (95% CI) 50 56 75.5 % 2.27 [ 1.07, 4.82 ]
Total events: 16 (AZA/6-MP), 8 (anti TNF- )
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
2 Over 12 months
Savarino 2013 13/17 2/16 24.5 % 6.12 [ 1.63, 22.97 ]
Subtotal (95% CI) 17 16 24.5 % 6.12 [ 1.63, 22.97 ]
Total events: 13 (AZA/6-MP), 2 (anti TNF- )
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0073)
Total (95% CI) 67 72 100.0 % 2.89 [ 1.50, 5.57 ]
Total events: 29 (AZA/6-MP), 10 (anti TNF- )
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Chi2 = 1.63, df = 1 (P = 0.20), I2 =39%
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Analysis 3.3. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 3 Endoscopic
relapse at 12 to 24 months (subgroup by drug type).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 3 Endoscopic relapse at 12 to 24 months (subgroup by drug type)
Study or subgroup AZA/6-MP anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azathioprine
Armuzzi 2013 5/10 1/11 20.3 % 5.50 [ 0.77, 39.39 ]
Lopez-Sanroman 2017 23/39 19/45 39.0 % 1.40 [ 0.91, 2.15 ]
Savarino 2013 11/17 1/16 20.7 % 10.35 [ 1.50, 71.32 ]
Subtotal (95% CI) 66 72 80.0 % 3.47 [ 0.75, 16.03 ]
Total events: 39 (AZA/6-MP), 21 (anti TNF- )
Heterogeneity: Tau2 = 1.27; Chi2 = 6.81, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 1.59 (P = 0.11)
2 6-mercaptopurine
Scapa 2015 4/8 1/11 20.0 % 5.50 [ 0.75, 40.36 ]
Subtotal (95% CI) 8 11 20.0 % 5.50 [ 0.75, 40.36 ]
Total events: 4 (AZA/6-MP), 1 (anti TNF- )
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
Total (95% CI) 74 83 100.0 % 3.67 [ 1.05, 12.81 ]
Total events: 43 (AZA/6-MP), 22 (anti TNF- )
Heterogeneity: Tau2 = 0.99; Chi2 = 8.44, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
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Analysis 3.4. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 4 Endoscopic
relapse (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 4 Endoscopic relapse (subgroup by length of follow-up)
Study or subgroup AZA/6-MP anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Armuzzi 2013 5/10 1/11 20.3 % 5.50 [ 0.77, 39.39 ]
Lopez-Sanroman 2017 23/39 19/45 39.0 % 1.40 [ 0.91, 2.15 ]
Scapa 2015 4/8 1/11 20.0 % 5.50 [ 0.75, 40.36 ]
Subtotal (95% CI) 57 67 79.3 % 2.44 [ 0.83, 7.18 ]
Total events: 32 (AZA/6-MP), 21 (anti TNF- )
Heterogeneity: Tau2 = 0.46; Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.62 (P = 0.10)
2 Over 12 months
Savarino 2013 11/17 1/16 20.7 % 10.35 [ 1.50, 71.32 ]
Subtotal (95% CI) 17 16 20.7 % 10.35 [ 1.50, 71.32 ]
Total events: 11 (AZA/6-MP), 1 (anti TNF- )
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
Total (95% CI) 74 83 100.0 % 3.67 [ 1.05, 12.81 ]
Total events: 43 (AZA/6-MP), 22 (anti TNF- )
Heterogeneity: Tau2 = 0.99; Chi2 = 8.44, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Chi2 = 1.64, df = 1 (P = 0.20), I2 =39%
0.01 0.1 1 10 100
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Analysis 3.5. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 5 Radiologic
relapse at 12 to 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 5 Radiologic relapse at 12 to 24 months
Study or subgroup AZA anti TNF- Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lopez-Sanroman 2017 26/39 22/45 1.36 [ 0.94, 1.98 ]
Savarino 2013 13/17 1/16 12.24 [ 1.80, 83.12 ]
0.01 0.1 1 10 100
Favours AZA Favours anti TNF-
Analysis 3.6. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 6 Histologic
relapse at 12 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 6 Histologic relapse at 12 months
Study or subgroup AZA anti TNF- Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armuzzi 2013 9/11 2/11 4.50 [ 1.25, 16.25 ]
0.01 0.1 1 10 100
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Analysis 3.7. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 7 Adverse
events at 12 to 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 7 Adverse events at 12 to 24 months
Study or subgroup AZA anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lopez-Sanroman 2017 18/39 20/45 41.6 % 1.04 [ 0.65, 1.66 ]
Savarino 2013 14/17 11/16 58.4 % 1.20 [ 0.81, 1.78 ]
Total (95% CI) 56 61 100.0 % 1.13 [ 0.83, 1.53 ]
Total events: 32 (AZA), 31 (anti TNF- )
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 8 Adverse
events (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 8 Adverse events (subgroup by length of follow-up)
Study or subgroup AZA/6-MP anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Lopez-Sanroman 2017 18/39 20/45 41.6 % 1.04 [ 0.65, 1.66 ]
Subtotal (95% CI) 39 45 41.6 % 1.04 [ 0.65, 1.66 ]
Total events: 18 (AZA/6-MP), 20 (anti TNF- )
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
2 Over 12 months
Savarino 2013 14/17 11/16 58.4 % 1.20 [ 0.81, 1.78 ]
Subtotal (95% CI) 17 16 58.4 % 1.20 [ 0.81, 1.78 ]
Total events: 14 (AZA/6-MP), 11 (anti TNF- )
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Total (95% CI) 56 61 100.0 % 1.13 [ 0.83, 1.53 ]
Total events: 32 (AZA/6-MP), 31 (anti TNF- )
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 3.9. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 9 Serious
adverse events at 12 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 9 Serious adverse events at 12 months
Study or subgroup AZA anti TNF- Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lopez-Sanroman 2017 4/39 9/45 0.51 [ 0.17, 1.54 ]
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Analysis 3.10. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 10
Withdrawal due to adverse events at 12 to 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 10 Withdrawal due to adverse events at 12 to 24 months
Study or subgroup AZA anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Armuzzi 2013 1/11 0/11 21.8 % 3.00 [ 0.14, 66.53 ]
Lopez-Sanroman 2017 9/39 1/45 49.5 % 10.38 [ 1.38, 78.36 ]
Savarino 2013 1/17 1/16 28.7 % 0.94 [ 0.06, 13.82 ]
Total (95% CI) 67 72 100.0 % 3.97 [ 0.92, 17.22 ]
Total events: 11 (AZA), 2 (anti TNF- )
Heterogeneity: Tau2 = 0.07; Chi2 = 2.08, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AZA Favours anti TNF-
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Analysis 3.11. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 11
Withdrawal due to adverse events (subgroup by length of follow-up).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 11 Withdrawal due to adverse events (subgroup by length of follow-up)
Study or subgroup AZA/6-MP anti TNF- Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months or less
Armuzzi 2013 1/11 0/11 21.4 % 3.00 [ 0.14, 66.53 ]
Lopez-Sanroman 2017 9/39 1/45 50.3 % 10.38 [ 1.38, 78.36 ]
Subtotal (95% CI) 50 56 71.7 % 7.17 [ 1.32, 38.96 ]
Total events: 10 (AZA/6-MP), 1 (anti TNF- )
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
2 Over 12 months
Savarino 2013 1/17 1/18 28.3 % 1.06 [ 0.07, 15.62 ]
Subtotal (95% CI) 17 18 28.3 % 1.06 [ 0.07, 15.62 ]
Total events: 1 (AZA/6-MP), 1 (anti TNF- )
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 67 74 100.0 % 4.17 [ 0.99, 17.47 ]
Total events: 11 (AZA/6-MP), 2 (anti TNF- )
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 1.39, df = 1 (P = 0.24), I2 =28%
0.01 0.1 1 10 100
Favours AZA/6-MP Favours anti TNF-
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Analysis 3.12. Comparison 3 Azathioprine or 6-mercaptopurine versus anti TNF-α, Outcome 12 HRQoL -
IBDQ > 170 at 24 months.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine or 6-mercaptopurine versus anti TNF-
Outcome: 12 HRQoL - IBDQ > 170 at 24 months
Study or subgroup AZA anti TNF- Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 2/17 14/16 0.13 [ 0.04, 0.50 ]
0.01 0.1 1 10 100
Favours AZA Favours anti TNF-
A D D I T I O N A L T A B L E S
Table 1. Key definitions and outcomes
Comparison Study ID Time from surgery
till recruitment
Site of surgery % /
exclusions
Clinical relapse
definition
Endoscopic / sur-
gical/ radiologic/
histological relapse
definition/
AZA & 6-MP versus Placebo
AZA versus Placebo
(12 months)
both arms 750 mg/
day metronidazole
(3 months)
D’Haens 2008 2 weeks Perforating disease
48
*Macroscopic evi-
dence for CD prox-
imally or distally to
the site of resection
or the presence of
frank pancolitis or
an ileorectal anasto-
mosis, patients with
a
stoma; operation for
fibrostenosis only
CDAI > 250 Rutgeerts i ≥ 2
6-MP 50 mg/day
versus Placebo
(24 months)
Hanauer 2004 Before
postoperative hospi-
tal discharge
N/A
* Active perianal dis-
ease or any active
disease in other seg-
ments of the intes-
Clinical re-
currence grading > 2
(Hanauer)
Rutgeerts i ≥ 2
Ra-
diographic relapse:
Radiographic recur-
rence grading > 2
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Table 1. Key definitions and outcomes (Continued)
tine
6-MP 1 mg/kg/day
versus Placebo
(3 years)
Mowat 2016 ≤ 3 months Ileal 39; Colonic 2;
Ileocolonic 59
* Need for further
surgery, stricturo-
plasty alone, forma-
tion of a stoma
CDAI > 150 and
a 100-point increase
from baseline
Rutgeerts i ≥ 2
HRQOL: IBDQ
scores
AZA & 6-MP vs 5-ASA
AZA 2 mg/kg versus
Mesalamine 3 mg/
kg (24 months)
Ardizzone 2004 Maximum 2 weeks Small bowel only
25.
3; Colon 5.6; Small
bowel and colon 9.
8; upper gastroin-
testinal tract 16.2
*Surgical pro-
cedures other than
conservative surgery
or for perianal dis-
ease only
CDAI > 200
Surgical
relapse: need for an-
other surgical proce-
dure
n/a
6-MP 50 mg/day
versus Mesalamine
3 g/day
(24 months)
Hanauer 2004 Before
postoperative hospi-
tal discharge
N/A
* Active perianal dis-
ease or any active
disease in other seg-
ments of the intes-
tine
clinical recurrence
grading > 2
Rutgeerts i ≥ 2
Radiographic re-
lapse: radiographic
recurrence grading >
2
AZA 2 mg/kg/day
versus Mesalamine
4 g/day
(12 months)
Reinisch 2010 6-24 months N/A
* Short
bowel syndrome, an
ileocolonic stoma
CDAI > 200 Rutgeerts i ≥ 2
HRQOL: IBDQ
AZA 2 mg/kg/day
versus Mesalazine 3
g/day
(24 months)
Savarino 2013 2-4 weeks Ileum 49,
Ileocolonic 51.
* Fibrostenotic stric-
ture, macroscop-
ically active disease
not resected at the
time of surgery, and
presence of a stoma
1. ≥ 2 on the clinical
recurrence grading
scale by Hanauer
2. CDAI > 200
Rutgeerts i≥2
Radiologic relapse:
≥ 2 radiographic
recurrence grading
scale
HRQl: IBDQ>170
AZA & 6-MP vs anti-TNF-α
AZA 2.5 mg versus
Infliximab 5 mg/kg
(12 months)
Armuzzi 2013 2-4 weeks Not reported
*Active perianal dis-
ease, presence of
stoma
HBI ≥ 8 Rutgeerts’ score ≥
i2
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Table 1. Key definitions and outcomes (Continued)
AZA 2 mg/kg/day
versus Adalimumab
(24 months)
Savarino 2013 2-4 weeks Ileum 49,
Ileocolonic 51.
* Fibrostenotic stric-
ture, macroscop-
ically active disease
not resected at the
time of surgery, and
presence of a stoma
1. ≥ 2 on the clinical
recurrence grading
scale by Hanauer
2. CDAI > 200
Rutgeerts i ≥ 2
Radiologic relapse:
≥ 2 radiographic
recurrence grading
scale
HRQl: IBDQ > 170
AZA 2.5 mg/kg/day
versus Adalimumab
(52 weeks)
both arms 750mg/
day metronidazole
(3 months)
Lopez-Sanroman
2017
2 weeks Ileal 58, ileocolonic
41
* Postsur-
gical stoma, resec-
tion for short indo-
lent stenosis, inac-
cessible anastomosis
to endoscopy
CDAI > 200 Rutgeerts i ≥ 2
6-MP 1.5 mg/kg/
day versus Adali-
mumab
(12 months)
Scapa 2015 < 45 days 6-MP 1.5 mg/kg/
day vs Placebo (12
months)
Scapa 2015 < 45 days
AZA: azathioprine; 6-MP: 6-mecarptopurine; mg: milligram; CD: Crohn’s disease; CDAI: Crohn’s disease activity index; NA: not
applicable; kg: kilogram; g: gram; HRQOL: health related quality of life; IBDQ: inflammatory bowel disease questionnaire; TNF:
tumour necrosis factor; HBI: Harvey Bradshaw index; 5-ASA: 5-aminosalicylic acid
Table 2. Summary of interventions and outcomes
Study ID Group 1 Group 2 Group 3 Relapse Quailty
of Life
Adverse
Events/
Serious
ad-
verse/ With-
drawal due to
adverse
events
Ardizzone
2004
Azathioprine
(2mg/kg/day)
Mesalamine
(3g/day)
Clinical: 32/
71 vs 35/71
Surgical: 26/
71 vs 21/71
n/a AE:18/71 vs
27/71
SAE:6/71 vs
15/71
Withdrwal
due to AE: 6/
71 vs 15/71
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Table 2. Summary of interventions and outcomes (Continued)
Armuzzi 2013 Azathioprine
(2.5 mg/kg/
day)
Infliximab
(5 mg/kg/day)
Infliximab
(5 mg/kg/day)
Clinical: 2/11
vs 1/11
Endoscopic:
5/11 vs 1/11;
Histologic: 9/
11 vs 2/11
n/a Withdrawal
due to AE: 0/
11 vs 1/11
D’Haens
2008
Metronida-
zole (750 mg/
day) first 3 mo
+
Azathioprine
(100-150 mg/
day)
Metronida-
zole (750mg/
day) first 3
months +
Placebo
Clinical: 11/
40 vs 19/41
En-
doscopic: 22/
40 vs 32/41
n/a AE: 3/40 vs 4/
41
Withdrawal
due to AE: 3/
40 vs 4/41
Hanauer 2004 6-Mercaptop-
urine (50 mg/
day)
Mesalamine
(3 g/day)
Placebo Clinical: 32/
47 vs 33/44 vs
35/40
n/a AE: 9/47 vs 6/
44 vs 4/40
SAE: 2/47 vs
0/44 vs 2/40
With-
drawal due to
AE: 9/47 vs 6/
44 vs 4/40
Lopez-
Sanroman
2017
Azathioprine
(2.5 mg/kg/d)
+ Metronida-
zole (750 mg/
day) first 3 mo
Adalimumab
+ Metronida-
zole (750 mg/
day) first 3 mo
Clinical: 14/
39 vs 7/45
En-
doscopic: 23/
39 vs 19/45
Radi-
ologic: 26/39
vs 22/45
n.
s. changes be-
tween groups
AE: 20/45 vs
18/39
SAE: 9/45 vs
4/39
Withdrawal
due to AE: 1/
39 vs 9/45
Mowat 2016 Mercaptop-
urine (1 mg/
kg/day)
Placebo Clinical: 66/
128 vs 70/112
Endoscopic:
90/128 vs 83/
112
n.s differences SAE: 3/128 vs
2/112
With-
drawal due to
AE: 39/128 vs
41/112
Reinisch 2010 Aza-
thioprine (2.
0-2.5 mg/kg/
d) + Placebo
mesalazine
Mesalazine
(4g/d) +
Placebo
azathioprine
Not included Mean IBDQ
change
AE: 34/37 vs
32/41
SAE: 0/37 vs
10/41
Withdrawal
due to AE: 1/
37 vs 10/41
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Table 2. Summary of interventions and outcomes (Continued)
Savarino 2013 Adalimumab
(160-80 mg 0-
2 weeks and
40 mg/week
thereafter)
Azathioprine
(2 mg/kg/day)
Mesalamine
(3 g/day)
Clinical by
Hanauer
score: 2/16 vs
12/17 vs 9/18
Clini-
cal by CDAI:
1/16 vs 12/17
vs 9/18
Endoscopic:
1/16 vs 11/17
vs 15/18
Radiologic:
1/16 vs 13/17
vs 15/18
HRQOL
(IBDQ >170):
14/16 vs 2/17
vs 3/18
AE:11/
16 vs 14/17 vs
14/18
With-
drawal due to
AE:0/16 vs 1/
17 vs 1/18
Scapa 2015 6-mercaptop-
urine (1.5 mg/
kg/day)
Adalimumab
(160-80-
40 mg/2 week
intervals)
Endoscopic:
4/8 vs 1/11
n/a n/a
mg: milligram; kg: kilogram; g: gram; CDAI: Crohn’s disease activity index; NA: not applicable; AE: adverse events; SAE: serious
adverse events; HRQOL: health related quality of life; IBDQ: inflammatory bowel disease questionnaire; ns: not significant
A P P E N D I C E S
Appendix 1. Search strategy July 26, 2018
PubMed
(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomised[tiab] OR placebo[tiab] OR drug therapy[sh] OR
randomly[tiab] OR trial[tiab] OR groups[tiab] NOT (animals [mh] NOT humans [mh]))
AND
(Crohn*[tiab] OR IBD tiab] OR Inflammatory bowel disease [tiab] OR [ Regional enteritis [tiab] OR ileitis [tiab])
AND
(surgery[tiab] OR surgic* [tiab] OR post-surgical [tiab] OR post-surgery [tiab] OR postoperative [tiab] OR post-operative [tiab] OR
resection [tiab] OR operation [tiab])
AND
(AZA[tiab] OR azathioprine [tiab] OR 6-mercaptopurine[tiab] OR 6MP[tiab] OR 6-MP[tiab] OR 6 anti-metabolite* [tiab] OR
antimetabolite* [tiab])
MEDLINE
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
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7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. randomized controlled trial/
14. or/1-13
15. exp Crohn disease/ or crohn*.mp.
16. inflammatory bowel disease.mp.
17. IBD.mp.
18. or/15-17
19. azathioprine.mp. or exp azathioprine derivative/ or exp azathioprine/
20. 6-mercaptopurine.mp. or exp mercaptopurine/
21. (AZA or 6-MP or 6MP).mp.
22. exp antimetabolite/ or anti-metabolite*.mp.
23. antimetabolite*.mp.
24. or/19-23
25. surgery.mp. or surgery/
26. (surgical or surgically).mp.
27. surgic*.mp.
28. (post-surgical or post-surgery).mp.
29. (postoperative or post-operative).mp.
30. resection.mp. or surgery/
31. operation.mp. or surgery/
32. or/25-31
33. 14 and 18 and 24 and 32
EMBASE
1 random$.tw.
2 factorial$.tw.
3 (crossover$ or cross over$ or cross-over$).tw.
4 placebo$.tw.
5 single blind.mp.
6 double blind.mp.
7 triple blind.mp.
8 (singl$ adj blind$).tw.
9 (double$ adj blind$).tw.
10 (tripl$ adj blind$).tw.
11 assign$.tw.
12 allocat$.tw.
13 crossover procedure/
14 double blind procedure/
15 single blind procedure/
16 triple blind procedure/
17 randomized controlled trial/
18 or/1-17
19. exp Crohn disease/ or crohn*.mp.
20. inflammatory bowel disease.mp.
21. IBD.mp.
22. or/19-21
23. azathioprine.mp. or exp azathioprine derivative/ or exp azathioprine/
24. 6-mercaptopurine.mp. or exp mercaptopurine/
25. (AZA or 6-MP or 6MP).mp.
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26. exp antimetabolite/ or anti-metabolite*.mp.
27. antimetabolite*.mp.
28. or/23-27
29. surgery.mp. or surgery/
30. (surgical or surgically).mp.
31. surgic*.mp.
32. (post-surgical or post-surgery).mp.
33. (postoperative or post-operative).mp.
34. resection.mp. or surgery/
35. operation.mp. or surgery/
36. or/29-35
37. 18 and 22 and 28 and 36
CENTRAL
#1 crohn* or “inflammatory bowel disease” or IBD
#2 anti-metabolite* or antimetabolite*
#3 6-mercaptopurine or mercaptopurine or 6-MP or 6MP
#4 AZA or azathioprine
#5 #2 or #3 or #4
# 6 #1 and #5
#7 surgery or surgic* or post-surgical or post-surgery or postoperative or post-operative or resection or operation
#8 #6 and #7
SR-IBD
Crohn AND 6-mercaptopurine or 6-MP or 6MP or azathioprine AND surgery or surgic* or post* or resection or operation (4)
Clinical trials.gov
1. Azathioprine and Crohn’s disease
2. 6-mercaptopurine and Crohn’s disease
WHO trial registry
1. Azathioprine and Crohn’s disease
2. 6-mercaptopurine and Crohn’s disease
W H A T ’ S N E W
Date Event Description
31 July 2019 New search has been performed New search and new studies added
31 July 2019 New citation required and conclusions have changed Updated review with new authors
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C O N T R I B U T I O N S O F A U T H O R S
Morris Gordon provided methodological expertise and performed screening of abstracts and titles, screening of full-text articles and
was involved with adjudication of GRADE analysis, manuscript preparation, critical revision of the manuscript, and approval of the
final manuscript.
Anthony K Akobeng provided methodological expertise and was involved with checking the data analyses, data interpretation,
manuscript preparation, critical revision for the manuscript, and approval of the final manuscript.
Zipporah Iheozor-Ejiofor performed adjudication in the screening and data extraction phases, data extraction, communication with
primary study authors, risk of bias assessments, GRADE analysis, manuscript preparation, critical revision for the manuscript and
approval of the final manuscript.
Teuta Gjuladin-Hellon performed data extraction, risk of bias assessments, statistical analyses, data interpretation, manuscript prepa-
ration, GRADE analysis, critical revision for the manuscript and approval of the final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
Teuta Gjuladin-Hellon: None known.
Zipporah Iheozor-Ejiofor: None known.
Morris Gordon: Received travel fees to attend international scientific and training meeting such as DDW, Advances in IBD, ESPGHAN,
BSPGHAN and Cochrane focused international events from companies including: Abbott, Nutricia, Biogaia, Ferring, Allergan, and
Tillots.
Anthony K Akobeng: None known.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
The scope of this review was expanded to include:
• Trials which compare AZA and 6-MP with no treatment were not included in the previous version of this review. If such trials
become available in future updates, we intend to analyse them separately from the placebo trials
• Inclusion criteria is limited to studies with minimum of 3 months of treatment versus 6 months in the previous review.
• Endoscopic recurrence was a primary outcome in the previous version of the review, however, we decided to report it as a
secondary outcome in this review to ensure consistency across the Cochrane IBD group portfolio.
• We also reported adverse event data as a composite outcome not individually as proposed in Gordon 2014 to ensure consistency
across the Cochrane IBD group portfolio
• Radiologic, surgical, histologic relapse and health related quality of life are additional outcomes which were only included in this
version of the review to ensure consistency across the Cochrane IBD group portfolio.
• We included abstracts in this review.
• For the previously published version of this review we contacted leaders in the field and drug manufacturers to identify
additional studies. We did not do this for the updated review.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Adalimumab; Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; Antibodies, Monoclonal [therapeutic use]; Antibodies, Mon-
oclonal, Humanized [therapeutic use]; Azathioprine [∗therapeutic use]; Crohn Disease [∗drug therapy; prevention & control; surgery];
Immunosuppressive Agents [∗therapeutic use]; Infliximab; Maintenance Chemotherapy [∗methods]; Mercaptopurine [∗therapeutic
use]; Mesalamine [therapeutic use]; Randomized Controlled Trials as Topic; Remission Induction [methods]; Secondary Prevention
MeSH check words
Humans
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